Skip to main content
Log in

Mitoxantrone

A Review of its Pharmacodynamic and Pharmacokinetic Properties, and Therapeutic Potential in the Chemotherapy of Cancer

  • Drug Evaluation
  • Published:
Drugs Aims and scope Submit manuscript

Summary

Synopsis

Mitoxantrone is a dihydroxyanthracenedione derivative which as intravenous mono- and combination therapy has demonstrated therapeutic efficacy similar to that of standard induction and salvage treatment regimens in advanced breast cancer, non- Hodgkin’s lymphoma, acute nonlymphoblastic leukaemia and chronic myelogenous leukaemia in blast crisis; it appears to be an effective alternative to the anthracycline component of standard treatment regimens in these indications. Mitoxantrone is also effective as a component of predominantly palliative treatment regimens for hepatic and advanced ovarian carcinoma. Limited studies suggest useful therapeutic activity in multiple myeloma and acute lymphoblastic leukaemia. Regional therapy of malignant effusions, hepatic and ovarian carcinomas has also been very effective, with a reduction in systemic adverse effects. Mitoxantrone inhibits DNA synthesis by intercalating DNA, inducing DNA strand breaks, and causing DNA aggregation and compaction, and delays cell cycle progression, particularly in late S phase In vitro antitumour activity is concentration- and exposure time- proportional, and synergy with other antineoplastic drugs has been demonstrated in murine tumour models

Leucopenia may be dose- limiting in patients with solid tumours, whereas stomatitis may be dose- limiting in patients with leukaemia. Other adverse effects are usually of mild or moderate severity although cardiac effects, particularly congestive heart failure, may be of concern, especially in patients with a history of anthracycline therapy, mediastinal irradiation or cardiovascular disease. Mitoxantrone displays an improved tolerability profile compared with doxorubicin and other anthracyclines, although myelosuppression may occur more frequently

Thus, mitoxantrone is an effective and better tolerated alternative to the anthracyclines in most haematological malignancies, in breast cancer and in advanced hepatic or ovarian carcinoma. Further studies may consolidate its role in the treatment of these and other malignancies

Pharmacodynamic Properties

Various human carcinoma cell lines are sensitive to mitoxantrone in vitro Synergism between mitoxantrone and cytarabine (cytosine arabinoside, ara-C), fluorouracil, vincristine, cisplatin, methotrexate, cyclophosphamide, thiotepa, dacarbazine (imidazole carboxamide), lucanthone and melphalan has been demonstrated in tumours in mice. Mitoxantrone produces concentration-and time-proportional delays in cell-cycle progression and although not considered cell-cycle specific, is most cytotoxic to cells in late S phase. It acts primarily on DNA, inducing DNA strand breaks by stabilising the topoisomerase-DNA cleavable complex and by free radical generation, and also induces DNA aggregation and compaction via electrostatic cross-linking. A cyclic derivative of mitoxantrone covalently binds DNA and may also be cytotoxic

Tumour cell resistance to mitoxantrone may be a result of increased P-glycoprotein expression, alteration of the levels or activity of topoisomerase II, enhanced DNA repair mechanisms or a combination of these and other mechanisms. Incomplete cross-resistance with anthracyclines has been observed in vitro Mitoxantrone has also demonstrated immunosuppressive, antiviral and potential antiangiogenic activities in pharmacodynamic studies. Preclinical studies also indicated a potential for mitoxantrone to induce adverse effects in the heart, the gastrointestinal tract and on blood formation

Pharmacokinetic Properties

The pharmacokinetics of mitoxantrone have been extensively studied in cancer patients, but methodological difficulties have resulted in a wide range of reported pharmacokinetic values. Following intravenous administration, disappearance of the drug from plasma generally follows triphasic kinetics, with respective half-lives of 3 to 10 minutes, 0.3 to 3.1 hours, and up to 12 days. Mitoxantrone is extensively distributed to body tissues, binds to endothelial surfaces, and penetrates blood cells and tumour tissues. It has a volume of distribution of up to 2248 L/m2. Plasma protein binding is approximately 78%

Mitoxantrone persists for prolonged periods in the tissues and was detectable in autopsy tissue from patients who last received the drug up to 272 days before death. Mitoxantrone appears to be excreted mainly in the bile, with about 10% of an administered dose appearing in the urine (65% in unchanged form) within 24 to 120 hours. Thus, dosage reduction should not be necessary in patients with impaired renal function. However, in patients with hepatic impairment or third space abnormalities (e.g. ascites) mitoxantrone elimination may be considerably prolonged and dosage reduction may be required. Regional administration of mitoxantrone (e.g. into the peritoneal or pleural space) has resulted in high local drug concentrations, which are sustained for long periods because of the slow rate of clearance from these cavities

Therapeutic Efficacy

Intravenous mitoxantrone monotherapy has demonstrated therapeutic efficacy similar to that of standard single-agent therapies in the treatment of advanced breast cancer, non-Hodgkin’s lymphoma, acute nonlymphoblastic leukaemia and chronic myelogenous leukaemia in blast crisis. Mitoxantrone substituted for the anthracycline component of standard combination salvage regimens produces similar efficacy, but often improves tolerability

Mitoxantrone is a useful component of induction chemotherapy regimens, particularly in haematological malignancies in combination with cytarabine. It has also proved useful as a component of low toxicity regimens designed for use in patients who are elderly or have a poor performance status. Limited studies suggest mitoxantrone therapy may be of benefit in patients with multiple myeloma or acute lymphoblastic leukaemia. Mitoxantrone has also been used as palliative therapy in patients with hepatic or advanced ovarian carcinoma — mitoxantrone stabilises the disease in a significant proportion of patients with poor prognosis and may also result in objective responses. Following regional administration mitoxantrone seems particularly useful in the treatment of malignant effusions. Intra-arterial treatment of hepatic carcinoma and breast carcinoma, and intraperitoneal therapy of ovarian carcinoma, have also proved successful

The role of consolidation and maintenance therapy in patients responding to mitoxantrone has not been investigated. Furthermore, additional studies are required to directly compare mitoxantrone with standard regimens in most treatment indications. The optimum combination of chemotherapy and surgery remains to be determined in advanced breast and ovarian carcinomas. Nonetheless, mitoxantrone is a generally effective alternative to the anthracycline component of treatment regimens for a number of malignant diseases and has also proved useful in various other combination chemotherapeutic regimens

Tolerability

Administered as mono- or combination therapy, the tolerability of mitoxantrone is generally superior to that of the anthracyclines such as doxorubicin with regard to the severity of nausea, vomiting, stomatitis, alopecia and cardiotoxicity; myelosuppression, however, may occur more frequently with mitoxantrone. Leucopenia (especially granulocytopenia) may be dose-limiting in patients with solid tumours, particularly those with hepatic dysfunction and/or poor performance status. Leucocyte nadirs occur 10 to 14 days after a single dose, usually with recovery by 21 days. Thrombocytopenia and mild anaemia are rare. Stomatitis may limit dosage in patients with leukaemia. Nausea and vomiting can occur in up to 60% and alopecia in 30% of patients but these symptoms are rarely severe. Abdominal pain may follow intraperitoneal mitoxantrone administration

Congestive heart failure, decreased left ventricular ejection fraction and arrhythmias have been reported in patients receiving mitoxantrone, particularly those with a history of anthracycline therapy, mediastinal irradiation or cardiovascular disease. The incidence of congestive heart failure appears to be dose-related but patients usually respond to cardiac glycoside and diuretic therapy

Dosage and Administration

The recommended intravenous dose of mitoxantrone is 14 mg/m2 once every 3 weeks in patients with solid tumours, reduced by 2 to 4 mg/m2 in patients with decreased marrow reserves, poor performance status or in those receiving combination chemotherapeutic regimens. If myelosuppression occurs, treatment should be withheld until haematological recovery with subsequent dosages titrated according to the severity and duration of this effect. In patients with leukaemia intravenous mitoxantrone 12 mg/m2/day for 5 days is recommended as monotherapy, or mitoxantrone 10 to 12 mg/m2/day for 3 days in combination with cytarabine. Mitoxantrone 8 mg/m2/day for 5 days has been used as monotherapy in paediatric leukaemia patients. Diluted mitoxantrone should be introduced slowly into the tube of a free-running intravenous solution. Cardiac monitoring is recommended in all patients, particularly those who have received large cumulative mitoxantrone dosages. Other administration methods and routes remain experimental and guidelines are not currently available

This is a preview of subscription content, log in via an institution to check access.

Access this article

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

References

  • Aapro MS, Alberts DS. Phase II trial of mitoxantrone in head and neck cancer. Investigational New Drugs 2: 329–330, 1984

    Article  PubMed  CAS  Google Scholar 

  • Alberts DS, Balcerzak SP, Bonnet JD, Stephens RL. Phase II trial of mitoxantrone in multiple myeloma: a Southwest Oncology Group Study. Cancer Treatment Reports 69: 1321–1323, 1985a

    PubMed  CAS  Google Scholar 

  • Alberts DS, Einspahr J, Bregman MD. Additive activity of mitoxantrone and doxorubicin in vitro against human breast cancer. Journal of Drug Development 1: 15–21, 1988

    Google Scholar 

  • Alberts DS, Peng YM, Bowden GT, Mackel C, Dalton WS. Mechanism of action and pharmacokinetics of Novantrone® in intravenous and intraperitoneal therapy. Proceedings of the Symposium on the current status of Novantrone Mar 21–24, 1985b

  • Alberts DS, Peng Y-M, Leigh S, Davis TP, Woodward DL. Disposition of mitoxantrone in cancer patients. Cancer Research 45: 1879–1884, 1985c

    PubMed  CAS  Google Scholar 

  • Alexander P, Evans R. Endotoxin and double stranded RNA render macrophages cytotoxic. Nature 323: 76–78, 1971

    Google Scholar 

  • Amadori S, Meloni G, Petti MC, Papa G, Miniero R, et al. Phase II trial of intermediate dose ARA-C (IDAC) with sequential mitoxantrone (MITOX) in acute myelogenous leukemia. Leukaemia 3: 112–114, 1989

    CAS  Google Scholar 

  • Ammon J, Katsohi D, Karstens JH. Radiotherapy with concurrent administration of mitoxantrone in patients with thyroid carcinoma. Abstract 9. Cancer Immunology and Immunotherapy 23 (Suppl.): A3, 1986

    Google Scholar 

  • Amrein PC, Davis RB, Mayer RJ, Schiffer CA. Treatment of relapsed and refractory acute myeloid leukemia with diaziquone and mitoxantrone: a CALGB phase I study. American Journal of Hematology 35: 80–83, 1990

    Article  PubMed  CAS  Google Scholar 

  • Andersson M, Philip P, Pedersen-Bjergaard J. High risk of therapy-related leukemia and preleukemia after therapy with prednimustine, methotrexate, 5-fluorouracil, mitoxantrone, and tamoxifen for advanced breast cancer. Cancer 65: 2460–2464, 1990

    Article  PubMed  CAS  Google Scholar 

  • Archimbaud E, Guyotat D, Devaux Y, Sebban C, Fière D. Aggressive sequential therapy with mitoxantrone VP-16 and cytarabine for resistant or relapsing acute myeloblastic leukemia (AML). Abstract. 4th International Symposium on Therapy of Acute Leukemias, p. 26, Rome, 1987

  • Arlin Z. Mitoxantrone (M): a review of safety in hematologic malignancies and solid tumors. Abstract. 4th International Symposium on Therapy of Acute Leukemias, p. 9, Rome, 1987

  • Arlin ZA, Berman E, Jhanwar S, Gams R, Schoch I, et al. Treatment of blastic transformation of chronic myelogenous leukemia with mitoxantrone. Cancer Chemotherapy and Pharmacology 17: 189–190, 1986

    Article  PubMed  CAS  Google Scholar 

  • Arlin Z, Case Jr DC, Moore J, Wiernik P, Feldman E, et al. Randomized multicenter trial of cytosine arabinoside with mitoxantrone or daunorubicin in previously untreated adult patients with acute nonlymphocytic leukemia (ANLL). Leukemia 4: 177–183, 1990

    PubMed  CAS  Google Scholar 

  • Auerbuch SD, Boldt M, Gaudinno G, Stern JB, Koch TH, et al. Experimental chemotherapy-induced skin necrosis in swine. Mechanistic studies of anthracycline antibiotic toxicity and protection with a radical dimer compound. Journal of Clinical Investigation 81: 142–148, 1988

    Article  Google Scholar 

  • Bachmann E, Weber E, Zbinden G. Effects of mitoxantrone and doxorubicin on energy metabolism of the rat heart. Cancer Treatment Reports 71: 361–366, 1987

    PubMed  CAS  Google Scholar 

  • Bailey N, Raghavan D, Shorthouse A. The response to chemotherapy of human breast tumour xenografts. Abstract 1061. Proceedings of the American Association of Cancer Research: p. 265, 1980

  • Bajetta E, Buzzoni R, Valagussa P, Bonadonna G. Mitoxantrone: an active agent in refractory non-Hodkin’s lymphomas. American Journal of Clinical Oncology-Cancer Clinical Trials 11: 100–103, 1988

    Article  CAS  Google Scholar 

  • Ballou RJ, Tseng MT. In vitro and in vivo responses of a murine transitional cell carcinoma to doxorubicin, mitoxantrone and aclacinomycin-A. Urological Research 14: 217–222, 1986

    Article  PubMed  CAS  Google Scholar 

  • Barton CM, Blackledge GRP, O’Brien M, Neoptolomos JA. A phase II study of epirubicin and mitoxantrone in advanced hepatobiliary and pancreatic carcinoma. Abstract. British Journal of Cancer 60: 459, 1989

    Google Scholar 

  • Basra J, Wolf CR, Brown JR, Patterson LH. Evidence for human liver mediated free-radical formation by doxorubicin and mitoxantrone. Anticancer Drug Design 1: 45–52, 1985

    CAS  Google Scholar 

  • Batra VK, Morrison JA, Woodward DL, Siverd NS, Yacobi A. Pharmacokinetics of mitoxantrone in man and laboratory animals. Drug Metabolism Reviews 17: 311–329, 1986

    Article  PubMed  CAS  Google Scholar 

  • Bellmunt J, Morales S, Navarro M, Sole L-A. Ifosfamide + mitoxantrone in advanced breast cancer previously treated with anthracyclines. Cancer Chemotherapy and Pharmacology 26 (Suppl.): S81–S84, 1990

    Article  PubMed  Google Scholar 

  • Benjamin RS, Chawla SP, Ewer MS, Carrasco CH, Mackay B, et al. Evaluation of mitoxantrone cardiac toxicity by nuclear angiography and endomyocardial biopsy: an update. Investigational New Drugs 3: 117–121, 1985

    Article  PubMed  CAS  Google Scholar 

  • Bennett JM, Muss HB, Doroshow JH, Wolff S, Krementz ET, et al. A randomized multicenter trial comparing mitoxantrone, cyclophosphamide, and fluorouracil with doxorubicin, cyclophosphamide, and fluorouracil in the therapy of metastatic breast carcinoma. Journal of Clinical Oncology 6(10): 1611–1620, 1988

    PubMed  CAS  Google Scholar 

  • Bernasconi C, Lazzarino M, Gherardi S, Amadori S, Mandelli F. Mitoxantrone as single agent in refractory acute leukaemia. In Bonadonna G (Ed.) Clinical progress with mitoxantrone. Royal Society of Medicine Services International Congress and Symposium Series 110, pp. 35–42, Royal Society of Medicine Services Limited, 1987

  • Bezwoda WR, Bernasconi C, Hutchinson RM, Winfield DA, de Bock R, et al. Mitoxantrone for refractory and relapsed acute leukemia. Cancer 66: 418–422, 1990

    Article  PubMed  CAS  Google Scholar 

  • Bezwoda WR, Dansey R, Seymour L. First-line chemotherapy of advanced breast cancer with mitoxantrone, cyclophosphamide and vincristine. Oncology 46: 208–211,1989

    Article  PubMed  CAS  Google Scholar 

  • Bezwoda WR, Hesdorffer C. The use of mitoxantrone plus cyclophosphamide as first-line treatment of metastatic breast cancer. Cancer 58: 1621–1624, 1986a

    Article  PubMed  CAS  Google Scholar 

  • Bezwoda WR, Hesdorffer CS. Mitoxantrone, methotrexate, and 5-flourouracil combination chemotherapy as first-line treatment in stage IV breast cancer. Cancer 57: 218–221, 1986b

    Article  PubMed  CAS  Google Scholar 

  • Bishop JF, Raghavan D, Woods R, Coates A, Burns I, et al. Mitomycin and mitoxantrone in previously treated patients with advanced breast cancer. Cancer Treatment Reports 71: 191–193, 1987

    PubMed  CAS  Google Scholar 

  • Björkholm M, Björnsdottir J, Stenke L, Grimfors G. Mitoxantrone, etoposide and cytarabine in the treatment of acute nonlymphocytic leukemia. Oncology 47: 112–114, 1990

    Article  PubMed  Google Scholar 

  • Blackledge G, Lawton F, Mould J, Latief T, Spooner D, et al. Mitoxantrone, an active agent in epithelial ovarian cancer. Phase-II studies and novel administration methods from the West Midlands Ovarian Cancer Group. In Bonadonna G (Ed.) Clinical progress with mitoxantrone. Royal Society of Medicine Services International Congress and Symposium Series 110, pp. 27–34, Royal Society of Medicine Services Limited, 1987

  • Blöchl-Daum B, Eichler HG, Rainer H, Jakesz R, Salzer H, et al. Escalating dose regimen of intraperitoneal mitoxantrone: phase I study — clinical and pharmacokinetic evaluation. European Journal of Cancer and Clinical Oncology 24(7): 1133–1138, 1988

    Article  Google Scholar 

  • Blöchl-Daum B, Eichler HG, Rainer H, Jakesz R, Salzer H, et al. Phase-I study of intraperitoneal mitoxantrone — clinical and pharmacokinetic evaluation. Onkologie 10: 54–56, 1987

    Article  PubMed  Google Scholar 

  • Boadle DJ, Tattersall MHN. Phase II study of mitoxantrone in advanced or metastatic endometrial carcinoma. Australian and New Zealand Journal of Obstetrics and Gynaecology 27: 341–342, 1987

    Article  PubMed  CAS  Google Scholar 

  • Bode U, Musch E. Systemic and pleural clearance of mitoxantrone after intrapleural application in patients with metastatic breast cancer. Abstract. 5th NCI-EORTC Symposium, Netherlands, p.9, 1986

    Google Scholar 

  • Bodey GP, Valdivieso M, Yap H-Y, Estey E, Bedikian A, et al. Early clinical trials of mitoxantrone. In Rozencweig M et al. (Eds) New anticancer drugs: mitoxantrone and bisantrene, pp. 103–114, Raven Press, New York, 1983

    Google Scholar 

  • Böhmer RM, Hoffmann K, Morstyn G. Hematoporphyrin derivative and anthracyclines mutually inhibit cellular uptake and toxicity. Cancer Chemotherapy and Pharmacology 20: 16–20, 1987

    Article  PubMed  Google Scholar 

  • Bonnern EM, Mitchell EP, Woolley PV, Smith FP, Neefe J, et al. Phase II trial of mitoxantrone in advanced colorectal cancer. Cancer Treatment Reports 66: 1995–1996, 1982

    Google Scholar 

  • Bowden GT, Roberts R, Alberts DS, Peng Y-M, Garcia D. Comparative molecular pharmacology in leukemic LI210 cells of the anthracene anticancer drugs mitoxantrone and bisantrene. Cancer Research 45: 4915–4920, 1985

    PubMed  CAS  Google Scholar 

  • Brambilla C, Moliterni A, Codazzi D, Villani F, Crippa F, et al. Mitoxantrone as first-salvage chemotherapy in relapsed breast cancer. Tumori 75: 145–149, 1989

    PubMed  CAS  Google Scholar 

  • Brito-Babapulle F, Catovsky D, Slocombe G, Newland AC, Marcus RE, et al. Phase II study of mitoxantrone and cytarabine in acute myeloid leukemia. Cancer Treatment Reports 71: 161–163, 1987

    PubMed  CAS  Google Scholar 

  • Brito-Babapulle F, Lord JAD, Whitmore DN. Treatment of RAEB- t with intensive chemotherapy and GM-CSF. Leukemia Research 13: 605–607, 1989

    Article  PubMed  CAS  Google Scholar 

  • Brodie GN, Elefanty A. Breast cancer. Advances in management. Drugs 35: 584–595, 1988

    Article  PubMed  CAS  Google Scholar 

  • Brook MG, Dunk AA, McDonald JA, Lever AML, Goh C, et al. Human lymphoblastoid interferon does not increase survival when added to mitozantrone in the treatment of hepatocellular carcinomas. Alimentary Pharmacology and Therapeutics 1:315–320, 1987

    Article  PubMed  CAS  Google Scholar 

  • Brusamolino E, Bertini M, Guidi S, Vitolo U, Inverardi D, et al. CHOP versus CNOP (N = mitoxantrone) in non-Hodgkin’s lymphoma: an interim report comparing efficacy and toxicity. Haematologica 73: 217–222, 1988

    PubMed  CAS  Google Scholar 

  • Bueno J, Julia A, Zuazu J, Lopez A, Massagué I, et al. Mitozantrone and cytarabine in the treatment of resistant acute leukemia. Abstract. 4th International Symposium on Therapy of Acute Leukemias, p. 27, Rome, 1987

  • Bull FE, VonHoff DD, Balcerzak SP, Stephens RL, Panettiere FJ. Phase II trial of mitoxantrone in advanced sarcomas: a Southwest Oncology Group Study. Cancer Treatment Reports 69:231–233, 1985

    PubMed  CAS  Google Scholar 

  • Burg G, Bieber T, Langecker P. Lokalisierte neutrophile ekkrine Hidradenitis unter Mitoxantron: eine typische Zytostatikane-benwirkung. Hautarzt 39: 233–236, 1988

    PubMed  CAS  Google Scholar 

  • Burghouts JTM. Mitoxantrone, methotrexate and chlorambucil in metastatic breast cancer, a combination with relatively low subjective toxicity. Netherlands Journal of Medicine 36: 43–45, 1990

    PubMed  CAS  Google Scholar 

  • Burns CP, Haugstad BN, Mossman CJ, North JA, Ingraham LM. Membrane lipid alteration: effect on cellular uptake of mitoxantrone. Lipids 23: 393–397, 1988

    Article  PubMed  CAS  Google Scholar 

  • Butler J, Hoey BM. Are reduced quinones necessarily involved in the antitumour activity of quinone drugs? British Journal of Cancer 55 (Suppl. 8): 53–59, 1987

    CAS  Google Scholar 

  • Büyükünal E, Derman U, Serdengecti S, Berkarda B. A clinical trial of mitoxantrone (novantrone) versus doxorubicin (adriamycin) in combination chemotherapy for metastatic breast cancer. Chemioterapia 6: 377–379, 1987

    PubMed  Google Scholar 

  • Capizzi RL, Cooper MR, Stuart J, Muss H, Richards F, et al. Continuous infusion (CI) mitoxantrone (MIT) in acute leukemia. Abstract 835. Proceedings of the American Association of Cancer Research 28: 210, 1987

    Google Scholar 

  • Capolongo L, Belvedere G, D’Incalci M. DNA damage and cytotoxicity of mitoxantrone and doxorubicin in doxorubicin-sensitive and -resistant human colon carcinoma cells. Cancer Chemotherapy and Pharmacology 25: 430–434, 1990

    Article  PubMed  CAS  Google Scholar 

  • Carmo-Pereira J, Costa FO, Henriques E, Cantinho-Lopes MG, Godinho F, et al. Primary chemotherapy with mitoxantrone and prednisone in advanced breast carcinoma. A phase II study. European Journal of Cancer and Clinical Oncology 24: 473–476, 1988

    Article  CAS  Google Scholar 

  • CaseJr DC, Gams RA, Golomb HM, Durkart G, Steinberg J. Phase II trial of mitoxantrone in non-Hodgkin’s lymphoma. Abstract 747. Blood 62 (5 Suppl. 1): 211a, 1983

    Google Scholar 

  • Cassidy J, Merrick MV, Smyth JF, Leonard RCF. Cardiotoxicity of mitozantrone assessed by stress and resting nuclear ventriculography. European Journal of Cancer and Clinical Oncology 24: 935–938, 1988

    Article  CAS  Google Scholar 

  • Cassileth P, Arlin Z, Silver R, Moore J, Bertino J, et al. Mitoxantrone therapy of relapsed and refractory acute leukaemia. Abstract. 3rd European Conference on Clinical Oncology and Cancer p. 10, Stockholm, 1985

  • Chandrasekaran B, Dimling J, Capizzi RL. Cross-resistance of menogaril and mitoxantrone in a subline of P388 leukemia resistant to doxorubicin. Cancer Treatment Reports 71: 195–196, 1987

    PubMed  CAS  Google Scholar 

  • Chang BK. Differential sensitivity of pancreatic adenocarcinoma cell lines to chemotherapeutic agents in culture. Cancer Treatment Reports 67: 355–361, 1983

    PubMed  CAS  Google Scholar 

  • Cheng CC, Zbinden G, Zee-Cheng RKY. Comparison of anti-neoplastic activity of aminoethylaminoanthraquinones and anthracycline antibiotics. Journal of Pharmaceutical Sciences 68: 393–396, 1979

    Article  PubMed  CAS  Google Scholar 

  • Chiccarelli FS, Morrison JA, Cosulich DB, Perkinson NA, Ridge DN, et al. Identification of human urinary mitoxantrone metabolites. Cancer Research 46: 4858–4861, 1986

    PubMed  CAS  Google Scholar 

  • Chiccarelli FS, Morrison JA, Gautam SR. Biliary pnarmacokinetics of 14 C-mitoxantrone in the rat following different intravenous doses and characteristics of drug-related material in the bile. Abstract 354. Federation Proceedings 43: 345, 1984

    Google Scholar 

  • Chisesi T, Capnist G, Rancan L, Santini G, Congiu M, et al. Impiego del mitoxantrone nella terapia dei linfomi non-Hodkin: risultati di uno studio in fase II in monochemioterapia o in associazione. Abstract 310. Tumori 75 (Suppl. 4): 100, 1989

    Google Scholar 

  • Chitnis MP, Satyamoorthy K, Pradhan SG, Advani SH. Modulation of sensitivity to mitoxantrone in human chronic myeloid leukemia cells by the antidepressant sintamil. Oncology 45: 292–296, 1988

    Article  PubMed  CAS  Google Scholar 

  • Chlebowski RT, Bulcavage L, Henderson IC, Woodcock T, Rivest R, et al. Mitoxantrone use in breast cancer patients with elevated bilirubin. Breast Cancer Research and Treatment 14: 267–274, 1989

    Article  PubMed  CAS  Google Scholar 

  • Chuang M-W, Tzeng C-H, Chiou T-J, Chiu C-F, Hsieh R-K, et al. A comparative trial of C-Novantrone OP(CNOP) vs C-Adriamycin OP(CHOP) in the treatment of stage II–IV malignant lymphoma — the preliminary report [in Chinese], Chinese Medical Journal (Taipei) 41: 51–56, 1988

    CAS  Google Scholar 

  • Clark GM, Tokaz LK, Von Hoff DD, Thoi LL, Coltman Jr CA. Cardiotoxicity in patients treated with mitoxantrone on Southwest Oncology Group Phase II protocols. Cancer Treatment Symposia 3: 25–30, 1984

    Google Scholar 

  • Coates A. Current status of chemotherapy of breast cancer. Drugs 28: 93–98, 1984

    Article  PubMed  CAS  Google Scholar 

  • Coates AS, Bishop J, Mann GJ, Raghavan D. Chemotherapy in metastatic melanoma: phase II studies of amsacrine, mitoxantrone and bisantrene. European Journal of Cancer and Clinical Oncology 22: 97–100, 1986

    Article  CAS  Google Scholar 

  • Cohen LF, Glaubiger DL, Kann HE, Kohn KW. Protein associated DNA single strand breaks and cytotoxicity of dihydroxyanthracenedione (DHAD), NSC-301739, in mouse LI210 leukemia cells. Abstract 1111. Proceedings of the American Association of Cancer Research 21: 277, 1980

    Google Scholar 

  • Coleman R, Clarke J, Gore M, Wiltshaw E, Slevin M, et al. A phase II study of mitozantrone in advanced carcinoma of the ovary. Cancer Chemotherapy and Pharmacology 24: 200–202, 1989

    Article  PubMed  CAS  Google Scholar 

  • Coleman RE, Maisey MN, Knight RK, Rubens RD. Mitoxantrone in advanced breast cancer — a phase II study with special attention to cardiotoxicity. European Journal of Cancer and Clinical Oncology 20: 771–776, 1984

    Article  CAS  Google Scholar 

  • ColtmanJr CA, Coltman TM, Balcerzak SP, Morrison FS, Von Hoff DD. Mitoxantrone in refractory nonHodgkin’s lymphoma. A Southwest Oncology Group study. Seminars in Oncology 11 (Suppl. 1): 50–53, 1984

    PubMed  Google Scholar 

  • ColtmanJr CA, McDaniel TM, Balcerzak SP, Morrison FS, Von Hoff DD. Mitoxantrone hydrochloride in lymphoma. Cancer Treatment Reviews 10 (Suppl. 8): 73–76, 1983

    Article  PubMed  Google Scholar 

  • Cornelia P, Abate G, Daponte A, Di Finizio G, Zarrilli D. Combinazione di mitoxantrone ifosfamide, methotrexate (MIM) nel salmataggio dei linfomi non Hodgkin. Abstract 313. Tumori 75 (Suppl. 4): 101, 1989

    Google Scholar 

  • Congiu A, Contu A, Chisesi T, Porcellini A, Rossi E, et al. Mitoxantrone in mono e polichemioterapia nei linfomi non- Hodgkin (LNH) dell’adulto ricadulti o refrattari. Rapporto del NHLCSG. Abstract 314. Tumori 75 (Suppl. 4): 101, 1989

    Google Scholar 

  • Corbett TH, Roberts BJ, Trader MW, Laster Jr WR, Griswold DP Jr, et al. Response of transplantable tumors of mice to anthracenedione derivatives alone and in combination with clinically useful agents. Cancer Treatment Reports 66: 1187–1200, 1982

    PubMed  CAS  Google Scholar 

  • Cornbleet MA, Stuart-Harris RC, Smith IE, Coleman RE, Rubens RD, et al. Mitoxantrone for the treatment of advanced breast cancer: single-agent therapy in previously untreated patients. European Journal of Cancer and Clinical Oncology 10: 1141–1146, 1984

    Article  Google Scholar 

  • Cowan JD, Von Hoff DD, McDonald B, Talley RW, McCracken JD, et al. Phase II trial of mitoxantrone in previously untreated patients with colorectal adenocarcinoma: a Southwest Oncology Group study. Cancer Treatment Reports 66: 1779–1780, 1982

    PubMed  CAS  Google Scholar 

  • Crespi MD, Ivanier SE, Genovese J, Baldi A. Mitoxantrone affects topoisomerase activities in human breast cancer cells. Biochemical and Biophysical Research Communications 136: 521–528, 1986

    Article  PubMed  CAS  Google Scholar 

  • Crossley RJ. Clinical safety and tolerance of mitoxantrone. Seminars in Oncology 11 (Suppl. 1): 54–58, 1984

    PubMed  CAS  Google Scholar 

  • Cruciani G, Tienghi A, Fiorentini G, Rosti G, Turci D, et al. Mitoxantrone (M) and vinblastine (V) in the treatment of advanced breast cancer. Tumori 76: 196–198, 1990

    PubMed  CAS  Google Scholar 

  • Dalton WS, Cress AE, Alberts DS, Trent JM. Cytogenetic and phenotypic analysis of a human colon carcinoma cell line resistant to mitoxantrone. Cancer Research 48: 1882–1888, 1988

    PubMed  CAS  Google Scholar 

  • Dalton WS, Durie BGM, Gerlach J, Cress AE, Alberts DS, et al. Development and characterization of a new drug resistant human multiple myeloma cell line. Abstract 766. Blood 66: 220a, 1985

    Google Scholar 

  • Dana B, Dahlberg S, Schnitzer B, Kjeidsberg CR, Jones SE, et al. Mitoxantrone, cisplatin, and methyl-glyoxal bis-guanylhydrazone chemotherapy for refractory malignant lymphoma: a Southwest Oncology Group Phase II Trial. Investigational New Drugs 7: 247–250, 1989

    Article  PubMed  CAS  Google Scholar 

  • Davis RB, Van Echo DA, Leone LA, Henderson ES. Phase II trial of mitoxantrone in advanced primary liver cancer: a cancer and leukemia group B study. Cancer Treatment Reports 70: 1125–1126, 1986

    PubMed  CAS  Google Scholar 

  • de Dycker RP, Timmermann J, Neumann RLA, Wever H, Schindler AE. Arterielle regionale Chemotherapie fortgeschrittener mammakarzinome. Deutsche Medizinische Wochenschrift 113: 1229–1233, 1988

    Article  PubMed  Google Scholar 

  • DeFabritiis P, Sandrelli A, Covelli A, Simone F, De Felice L, et al. In vitro pharmacological purging of human bone marrow is enhanced by the use of lonidamine. Experimental and Molecular Pathology 50: 210–219, 1989

    Article  PubMed  Google Scholar 

  • De Jager R, Cappelaere P, Armand JP, Keiling R, Fargeot P, et al. An EORTC Phase II study of mitoxantrone in solid tumours and lymphomas. European Journal of Cancer and Clinical Oncology 20: 1369–1375, 1984

    Article  Google Scholar 

  • de Jong S, Zijlstra JG, de Vries EGE, Mulder NH. Reduced DNA topoisomerase II activity and drug-induced DNA cleavage activity in an adriamycin-resistant human small cell lung carcinoma cell line. Cancer Research 50: 304–309, 1990

    PubMed  Google Scholar 

  • DeSimone PA, Gams R, Bartolucci A. Phase II studies of mitoxantrone (dihydroxyanthracenedione) in the treatment of advanced colorectal carcinoma. American Journal of Clinical Oncology-Cancer Clinical Trials 7: 517–522, 1984

    Article  Google Scholar 

  • DeSimone PA, Gams R, Bartolucci A. Weekly mitoxantrone in the treatment of advanced pancreatic carcinoma: a Southeastern Cancer Study Group trial. Cancer Treatment Reports 70: 929–930, 1986a

    Google Scholar 

  • DeSimone PA, Gams R, Birch R. Phase II evaluation of mitoxantrone in advanced carcinoma of the stomach: a Southeastern Cancer Study Group trial. Cancer Treatment Reports 70: 1043–1044, 1986b

    Google Scholar 

  • Dharmasena F. Novantrone and ARA-C in acute leukaemia. Proceedings of the 2nd UK Novantrone Symposium, pp. 5–10, 1986

  • Dharmasena F, Chu AC, Goldman JM, Galton DAG. Mitozantrone-induced asteatosis. Correspondence. Lancet 2: 101, 1985

    Article  PubMed  CAS  Google Scholar 

  • Dietel M, Arps H, Gerding D, Trapp M, Sieck M, et al. Effectiveness of mitoxantrone on the proliferation of cell cultures derived from malignant mesenchymal tumors of human origin. Journal of Cancer Research and Clinical Oncology 114: 197–203, 1988

    Article  PubMed  CAS  Google Scholar 

  • Donadio M, Bonardi GM, Iberti V, Bretti S, Calciati A. Mitoxantrone (MXT) in monochemioterapia (mono CT) nel carcinoma polmonare avanzato non a piccole cellule (NSCLC): studio di fase II. Abstract 265. Tumori 75 (Suppl. 4): 86, 1989

    Google Scholar 

  • Dorfman RF, Burke JS, Berard CW. A working formulation of non-Hodgkin’s lymphomas: background, recommendations, histological criteria, and relationship to other classifications. In Rosenberg SA & Kaplas HS (Eds) Malignant lymphomas. etiology, immunology, pathology, treatment pp. 351–368, Academic Press, New York, 1976

    Google Scholar 

  • Doroshow JH, Davies KJA. Comparative cardiac oxygen radical metabolism by anthracycline antibiotics. Mitoxantrone, bisantrene, 4′-(9-acridinylamino)-methanesulfon-m-anisidide and neocarzinostatin. Pharmacology 32: 2935–2939, 1983

    CAS  Google Scholar 

  • Dorr RT, Alberts DS, Soble M. Lack of experimental vesicant activity for the anticancer agents cisplatin, melphalan, and mitoxantrone. Cancer Chemotherapy and Pharmacology 16: 91–94, 1986

    Article  PubMed  CAS  Google Scholar 

  • Drewinko B, Yang L-Y, Barlogie B, Trujillo JM. Comparative cytotoxicity of bisantrene, mitoxantrone, ametantrone, dihydroxyanthracenedione, dihydroxyanthracenedione diacetate, and doxorubicin on human cells in vitro. Cancer Research 43: 2648–2653, 1983

    PubMed  CAS  Google Scholar 

  • Dukart G, Iatropoulos MJ, Yacobi A. Comment on mitoxantrone. Drug Intelligence and Clinical Pharmacy 19: 216–218, 1985

    PubMed  CAS  Google Scholar 

  • Dulak L, Manandhar M, Iatropoulos MJ, Noble JF. Cytogenetic analysis of bone marrow of rats treated with mitoxantrone hydrochloride, an antineoplastic agent. Abstract 134. Proceedings of the American Association for Cancer Research 23: 35, 1982

    Google Scholar 

  • Durr FE. Biologic and biochemical effects of mitoxantrone. Seminars in Oncology 11 (Suppl. 1): 3–10, 1984

    PubMed  CAS  Google Scholar 

  • Editorial. Multidrug resistance in cancer. Lancet 2: 1075–1076, 1989

  • Ehninger G, Aapro MS, Rainer H, Blochl-Daum B. Intracavitary treatment with mitoxantrone. In Mouridsen & Arlin (Eds) The role of mitoxantrone in malignant disease (Pharmamanual), pp. 19–25, PharmaLibri, Chicago, 1987a

    Google Scholar 

  • Ehninger G, Fackler-Schwalbe E, Freund M, Heil G, Henke M, et al. Combination of mitoxantrone and etoposide in patients aged over 60 years with untreated acute myelogenous leukemia. Haematology and Blood Transfusion 33: 316–317, 1990a

    Article  PubMed  CAS  Google Scholar 

  • Ehninger G, Ho AD, Meyer P, Mjaaland I, Ostendorf P, et al. Mitoxantrone in the treatment of relapsed and refractory acute leukemia. Onkologie 8: 146–148, 1985

    Article  PubMed  CAS  Google Scholar 

  • Ehninger G, Mjaaland I, Proksch B, Schiller E, Meyer P. Klinische Pharmacokoiogie von Mitoxantron bei Patienten mit Mammakarzinom und Leukämien. Zeitschrift für antimikrobielle antineoplastische Chemotherapie 2: 67–70, 1987b

    Google Scholar 

  • Ehninger G, Proksch B, Hartmann F, Gartner H-V, Wilms K. Mitoxantrone metabolism in the isolated perfused rat liver. Cancer Chemotherapy and Pharmacology 12: 50–52, 1984a

    Article  PubMed  CAS  Google Scholar 

  • Ehninger G, Proksch B, Heinzel G, Woodward DL. Clinical pharmacology of mitoxantrone. Cancer Treatment Reports 70: 1373–1378,1986

    PubMed  CAS  Google Scholar 

  • Ehninger G, Schüler U, Proksch B, Zeller K-P, Blanz J. Pharmacokinetics and metabolism of mitoxantrone: a review. Clinical Pharmacokinetics 18: 365–380, 1990b

    Article  PubMed  CAS  Google Scholar 

  • Ehninger G, Weible KH, Heidemann EG, Waller HD. Mitoxantrone and cyclophosphamide in patients with advanced breast cancer. Cancer Treatment Reports 68: 1283–1284, 1984b

    PubMed  CAS  Google Scholar 

  • Eisenhauer EA, Evans WK, Raghavan D, Desmeules MJ, Murray NR, et al. Phase II study of mitoxantrone in patients with mesothelioma: a National Cancer Institute of Canada Clinical Trials Group study. Cancer Treatment Reports 70: 1029–1030, 1986

    PubMed  CAS  Google Scholar 

  • Esseesse I, Bartolucci AA, Gams RA, Silberman H, Velez-Garcia E, et al. Weekly mitoxantrone therapy for refractory multiple myeloma: a Southeastern Cancer Study Group trial. Cancer Treatment Reports 70: 669–670, 1986

    PubMed  CAS  Google Scholar 

  • Estey EH, Keating MJ, McCredie KB, Bodey GP, Freireich EJ. Phase II trial of mitoxantrone in refractory acute leukemia. Cancer Treatment Reports 67: 389–390, 1983

    PubMed  CAS  Google Scholar 

  • Ettinger DS, Finkelstein DM, Harper GR, Ruckdeschel JC, Yuang-Chi A, et al. Phase II study of mitoxantrone, aclarubicin, and diaziquone in the treatment of non-small cell lung carcinoma: an Eastern Cooperative Oncology Group study. Cancer Treatment Reports 69: 1033–1034, 1985

    PubMed  CAS  Google Scholar 

  • Evensen SA, Brinch L, Wisloff F. Residiv eller behandlingsresistens a.v akutt myelogen leukemi. Effekt av mitoksantron og cytosin arabinosid. Tidsskrift for Den Norske Laegeforening 109: 2004–2006, 1989

    PubMed  CAS  Google Scholar 

  • Falkson G, Coetzer BJ, Terblanche APS. Phase II trial of mitoxantrone in patients with primary liver cancer. Cancer Treatment Reports 68: 1311–1312, 1984

    PubMed  CAS  Google Scholar 

  • Falkson G, Klein B, Falkson H. Hematological toxicity: experience with anthracyclines and anthracenes. Experimental Hematology 13 (Suppl. 16): 64–71, 1985

    PubMed  CAS  Google Scholar 

  • Falkson G, Ryan LM, Johnson LA, Simson IW, Coetzer BJ, et al. A random phase II study of mitoxantrone and cisplatin in patients with hepatocellular carcinoma. An ECOG Study. Cancer 60: 2141–2145, 1987

    Article  PubMed  CAS  Google Scholar 

  • Feuilhade F, Brun B, Calitchi E, Otzmeguine Y, Haddad E, et al. Efficacite et toxicile de la mitoxantrone par voie intrapleurale: a propos de 18 cas de metastases pleurales de cancer du sein. Bulletin du Cancer 76: 361–365, 1989

    PubMed  CAS  Google Scholar 

  • Fidler JM, DeJoy QS, Gibbons Jr JJ. Selective immunomodulaion by the antineoplastic agent mitoxantrone. I. Suppression of B lymphocyte function. Journal of Immunology 137: 727–732, 1986a

    CAS  Google Scholar 

  • Fidler JM, DeJoy Quinn S, Smith FR, Gibbons JJ. Selective immunomodulation by the antineoplastic agent mitoxantrone. II. Nonspecific adherent suppressor cells derived from mitoxantrone-treated mice. Journal of Immunology 136: 2747–2754, 1986b

    CAS  Google Scholar 

  • Fiorentino MV, Nicoletto MO, Stefani G, Salvagno L, Tredese F. A phase II trial with mitoxantrone in pretreated epithelial ovarian cancer. Abstract. 6th Mediterranean Congress Chemotherapy, Italy, p. 20, 1988

  • Fisher GR, Maine JE, Cairns D, Patterson LH. Comparison of free radical generation by doxorubicin and mitozantrone in MCF-7 human breast cancer cells. Journal of Pharmacy and Pharmacology 41 (Suppl.): 23P, 1989

    Google Scholar 

  • Fisher GR, Patterson LH. Oxidative activation of the antitumour agent mitozantrone. Journal of Pharmacy and Pharmacology 41 (Suppl.): 150P, 1989

    Google Scholar 

  • Foggi CM, Megale C, Morera E, Giglio A, Iannelli A. Chemoterapia del microcitoma con cisplatino (C) + mitoxantrone (M) e etoposide (E) + ifosfamide (I) alternati risultati preliminari di eno studio in fase II. Abstract 248. Tumori 75 (Suppl. 4): 187, 1989

    Google Scholar 

  • Follézou JY, Pouillart P, Grimbert J, Daban A, Favre R, et al. Prospective randomised study comparing doxorubicin to mitoxantrone in advanced breast cancer (CAF vs CNF). Abstract 2823. 1.4th International Cancer Congress, p. 734, 1986

  • Ford JM, Panasci L, Leclerc Y, Margolese R. Phase II trial of a combination of doxorubicin and mitoxantrone in metastatic breast cancer. Cancer Treatment Reports 71: 921–925, 1987

    PubMed  CAS  Google Scholar 

  • Foss-Abrahamsen A, Lenner P, Hedenus M, Landys K, Noppa H. Mitoxantrone in the treatment of patients with non-Hodgkin’s lymphoma. Cancer Treatment Reports 71: 1209–1212, 1987

    PubMed  CAS  Google Scholar 

  • Foster BJ, Lev L, Bergemann C, Marsoni S. Cardiac events in phase II trials with mitoxantrone. Cancer Treatment Symposia 3: 43–46, 1984

    Google Scholar 

  • Fountzilas G, Inoue S, Ohnuma T. Schedule-dependent interaction of cytarabine plus doxorubicin or cytarabine plus mitoxantrone in acute myelocytic leukemia cells in culture. Leukemia 4: 321–324, 1990

    PubMed  CAS  Google Scholar 

  • Fountzilas G, Ohnuma T, Okano T, Greenspan EM, Holland JF. Schedule-dependent synergism of cytosine arabinoside (ARA-C) with mitoxantrone in human acute myelogenous leukemia cell line HL-60. Abstract C-699. Proceedings of the American Society of Clinical Oncology, p. 179, 1983

  • Fountzilas G, Ohnuma T, Rammos K, Mindich B, Holland JF. Comparison of mitoxantrone and ametantrone in human acute myelocytic leukemia cells in culture and in bone marrow granulocyte-macrophage progenitor cells. Cancer Drug Delivery 3: 93–100, 1986

    Article  PubMed  CAS  Google Scholar 

  • Foye WO, Vajragupta O, Sengupta SK. DNA-binding specificity and RNA polymerase inhibitory activity of bis-(aminoalkyl)anthraquinones and bis(methylthio)vinyl-quinolinium iodides. Journal of Pharmaceutical Sciences 71: 253–257, 1982

    Article  PubMed  CAS  Google Scholar 

  • Frank P, Novak RF. Effects of mitoxantrone and bisantrene on platelet aggregation and prostaglandin/thromboxane biosynthesis in vitro. Anticancer Research 6: 941–948, 1986

    PubMed  CAS  Google Scholar 

  • Fraschini G, Yap H-Y, Mann G, Buzdar AU, Blumenschein GR, et al. Chemotherapy with mitoxantrone in combination with continuous infusion vinblastine for metastatic breast cancer. Cancer 60: 1724–1728, 1987

    Article  PubMed  CAS  Google Scholar 

  • Frasci G, Pacelli R, Scala S, Facchini G, Rinaldi L, et al. Intra-peritoneal mitoxantrone via temporary catheter in patients with ovarian cancer: toxicity and feasibility evaluation. Advances in Therapy 7: 124–135, 1990

    Google Scholar 

  • French-American-British (FAB) Co-operative Group, Bennett JM, Catovsky D, Daniel M-T, Flandrin G, et al. Proposals for the classification of the acute leukaemias. British Journal of Haematology 33: 451–458, 1976

    Article  PubMed  CAS  Google Scholar 

  • Fujimoto S, Ogawa M. Antitumor activity of mitoxantrone against murine experimental tumors: comparative analysis against various antitumor antibiotics. Cancer Chemotherapy and Pharmacology 8: 157–162, 1982

    Article  PubMed  CAS  Google Scholar 

  • Gad-El-Mawla N, Macdonald J. A phase II study of mitoxantrone in advanced head and neck cancer and advanced breast cancer. Abstract. Investigational New Drugs 2: 117, 1984

    Google Scholar 

  • Gams RA, Nelson O, Birch R. Phase II evaluation of mitoxantrone in advanced renal cell carcinoma: a Southeastern Cancer Study Group trial. Cancer Treatment Reports 70: 921–922, 1986

    PubMed  CAS  Google Scholar 

  • Gams RA, Steinberg J, Posner L. Mitoxantrone in malignant lymphoma. Seminars in Oncology 11 (Suppl. 1): 47–49, 1984

    PubMed  CAS  Google Scholar 

  • Gams RA, Wesler MJ. Mitoxantrone cardiotoxicity: results from Southeastern Cancer Study Group. Cancer Treatment Symposia 3: 31–33, 1984

    Google Scholar 

  • Gerlach JH, Kartner N, Bell DR, Ling V. Multidrug resistance. Cancer Surveys 5: 25–46, 1986

    PubMed  CAS  Google Scholar 

  • Gervásio H, Santos JG, Abraul E, Amaral N, et al. Phase II trial of mitoxantrone (NVT) and cyclophosphamide (CTX) in advanced breast cancer. Abstract 128. Cancer Immunology and Immunotherapy 23 (Suppl.): A32, 1986

    Google Scholar 

  • Gibby EM, Boyse O, Hill BT. Selective interactions of verapamil with anthraquinones in adriamycin-sensitive and -resistant murine and human tumour cell lines in vitro. Cancer Chemotherapy and Pharmacology 20: 5–7, 1987

    Article  PubMed  CAS  Google Scholar 

  • Goldenberg A, Kelsen D, Benedetto P. Phase II trial of mitoxantrone in advanced gastric cancer. Oncology 45: 273–275, 1988

    Article  PubMed  CAS  Google Scholar 

  • Gonsette RE, Demonty L. Immunosuppression with mitoxantrone in multiple sclerosis: a pilot study for 2 years in 22 patients. Abstract 537P. Neurology 40 (Suppl. 1): 261, 1990

    Google Scholar 

  • Gray MA, Novak RF. Comparative studies on the antioxidant properties of mitoxantrone, ametantrone and bisantrene. Abstract 876. Proceedings of the American Association for Cancer Research 26: 223, 1985

    Google Scholar 

  • Green RM, Stewart DJ, Hugenholtz H, Richard MT, Thibault M, Montpetit V. Human central nervous system and plasma pharmacology of mitoxantrone. Journal of Neuro-Oncology 6: 75–83, 1988

    Article  PubMed  CAS  Google Scholar 

  • Greidanus J, de Vries EGE, Mulder NH, Sleijfer DTh, Uges DRA, et al. A phase I pharmacokinetic study of 21-day continuous infusion mitoxantrone. Journal of Clinical Oncology 7: 790–797, 1989

    PubMed  CAS  Google Scholar 

  • Griffiths KD, Parry DH. Hypomagnesaemia and hypocalcaemia after treatment with mitoxantrone. British Medical Journal 297: 488, 1988

    Article  PubMed  CAS  Google Scholar 

  • Gröhn P, Kumpulainen E, Taskinen P, Blanco G, Hakala T, et al. A comparative randomised study of mitoxantrone and doxorubicin combination chemotherapy in advanced breast cancer. Abstract 347. Investigational New Drugs 7: 435, 1989

    Google Scholar 

  • Guglielmi C, Gherlinzoni F, Amadori S, Mazza P, Mantovani L, et al. A phase III comparative trial of m-BACOD vs m-BNCOD in the treatment of stage II-IV diffuse non-Hodgkin’s lymphomas. Haematologica 74: 563–569, 1989

    PubMed  CAS  Google Scholar 

  • Hall C, Dougherty WJ, Lebish IJ, Brock PG, Man A. Warning against use of intrathecal mitoxantrone. Correspondence. Lancet 1: 734, 1989

    Article  PubMed  CAS  Google Scholar 

  • Hall VL, Buchanan RB, Williams CJ. Comparison of toxicity of mitozantrone and doxorubicin when used in combination with vincristine and prednisolone for advanced breast cancer. Abstract. British Journal of Cancer 58(2): 263, 1988

    Google Scholar 

  • Hansen SW, Nissen NI, Hansen MM, Hou-Jensen K, Pedersen-Bjergaard J. High activity of mitoxantrone in previously untreated low-grade lymphomas. Cancer Chemotherapy and Pharmacology 22: 77–79, 1988

    Article  PubMed  CAS  Google Scholar 

  • Harker WG, Slade DL, Dalton WS, Meltzer PS, Trent JM. Multi-drug resistance in mitoxantrone-selected HL-60 leukemia cells in the absence of P-glycoprotein overexpression. Cancer Research 49: 4542–4549, 1989

    PubMed  CAS  Google Scholar 

  • Harris AL, Cantwell BMJ, Carmichael J, Wilson R, Farndon J, et al. Comparison of short-term and continuous chemotherapy (mitozantrone) for advanced breast cancer. Lancet 335: 186–190, 1990

    Article  PubMed  CAS  Google Scholar 

  • Hausmaninger H, Lehnert M, Steger G, Sevelda P, Michlmayr G, et al. Vindesine-epirubicin versus vindesine-mitoxantrone in metastatic breast cancer. Onkologie 12: 225–229, 1989

    Article  PubMed  CAS  Google Scholar 

  • Hayward JL, Carbone PP, Heuson J-C, Kumaoka S, Segaloff A, et al. Assessment of response to therapy in advanced breast cancer. European Journal of Cancer 18: 89–94, 1977

    Google Scholar 

  • Heidemann E, Steinke B, Hartlapp J, Schumacher K, Possinger K, et.-al. Randomized clinical trial comparing mitoxantrone with epirubicin and with doxorubicin, each combined with cyclophosphamide in the first-line treatment of patients with metastatic breast cancer. Onkologie 13: 24–27, 1990

    Article  PubMed  CAS  Google Scholar 

  • Heinemann V, Murray D, Walters R, Meyn RE, Plunkett W. Mitoxantrone-induced DNA damage in leukemia cells is enhanced by treatment with high-dose arabinosylcytosine. Cancer Chemotherapy and Pharmacology 22: 205–210, 1988

    Article  PubMed  CAS  Google Scholar 

  • Heinz R, Baumgartner G, Waldner R, Fortelny A. Preliminary results of a new drug combination (VIM) in the treatment of non-Hodgkin lymphomas (NHL). Abstract 10. Congress of the Austrian and German Societies of Hematology and Oncology, p. 148, 1985

  • Hellmann K, Hutchinson GE, Henry K. Effect of high dose mitozantrone with Cronassial on the Lewis lung carcinoma and L1210leukaemia. Clinical and Experimental Metastasis 5: 157–163, 1987

    Article  PubMed  CAS  Google Scholar 

  • Henderson BM, Dougherty WJ, James VC, Tilley LP, Noble JF. Safety assessment of a new anticancer compound, mitoxantrone, in beagle dogs: comparison with doxorubicin. I. Clinical observations. Cancer Treatment Reports 66: 1139–1143, 1982

    PubMed  CAS  Google Scholar 

  • Henderson IC, Allegra JC, Woodcock T, Wolff S, Bryan S, et al. Randomized clinical trial comparing mitoxantrone with doxorubicin in previously treated patients with metastatic breast cancer. Journal of Clinical Oncology 7: 560–571, 1989

    PubMed  CAS  Google Scholar 

  • Henney JE, DeVita VT. Breast cancer. In Braunwald et al. (Eds) Harrison’s principles of internal medicine, 1lth ed., Vol. 2, pp. 1567–1574, McGraw-Hill, New York, 1987

    Google Scholar 

  • Herman TS. Effect of temperature on the cytotoxicity on vindesine, amsacrine, and mitoxantrone. Cancer Treatment Reports 67: 1019–1022, 1983

    PubMed  CAS  Google Scholar 

  • Hernandez R, Gibbons J, Fidler JM. B lymphocyte effects of mitoxantrone. Abstract 14. Agents and Actions 16: 606–607, 1985

    Google Scholar 

  • Hibbs JB, Lambert LH, Remington JS. Possible role of macrophage mediated nonspecific cytotoxicity in tumour resistance. Nature New Biology 235: 48–50, 1972

    PubMed  Google Scholar 

  • Hiddemann W, Aul C, Maschmever G, Lathan B, Koppler H, Hoffmann R, et al. Age related randomized comparison of sequentially applied high-dose versus intermediate dose cytosine arabinoside in combination with mitoxantrone (S-HAM) in the treatment of relapsed and refractory acute myeloid leukemia: study design and preliminary results. Onkologie 12: 4–6, 1989

    Article  PubMed  CAS  Google Scholar 

  • Hiddemann W, Büchner Th, Essink M, Koch O, Stenzinger W, et al. High-dose cytosine arabinoside and mitoxantrone: preliminary results of a pilot study with sequential application (S- HAM) indicating a high antileükemic activity in refractory acute leukemias. Onkologie 11: 10–12, 1988

    Article  PubMed  CAS  Google Scholar 

  • Hiddemann W, Buchner T, Heil G, Schumacher K, Diedrich H, et al. Treatment of refractory acute lymphoblastic leukemia in adults with high dose cytosine arabinoside and mitoxantrone (HAM). Leukemia 4: 637–640, 1990a

    PubMed  CAS  Google Scholar 

  • Hiddemann W, Kreutzmann H, Straif K, Ludwig W-D, Mertels-mann R, et al. High-dose cytosine arabinoside in combination with mitoxantrone for the treatment of refractory acute myeloid and lymphoblastic leukemia. Seminars in Oncology 14: 73–77, 1987

    PubMed  CAS  Google Scholar 

  • Hiddemann W, Schmitz N, Pfreundschuh M, Pflüger K-H, Ollech-Chwoyka J, et al. Treatment of refractory Hodgkin’s disease with high-dose cytosine arabinoside and mitoxantrone in combination. Results of a clinical phase II study of the German Hodgkin study group. Cancer 66: 838–843, 1990b

    Article  PubMed  CAS  Google Scholar 

  • Hilgers RO, Von Hoff DD, Stephens RL, Boutselis JG. Mitoxantrone and advanced squamous cell carcinoma of the cervix: a Southwest Oncology Group study. Cancer Treatment Reports 70: 527–528, 1986

    PubMed  CAS  Google Scholar 

  • Hilgers RD, Von Hoff DD, Stephens RL, Boutselis JG, Rivkin SE. Mitoxantrone in adenocarcinoma of the endometrium: a Southwest Oncology Group study. Cancer Treatment Reports 69: 1329–1330, 1985

    PubMed  CAS  Google Scholar 

  • Hilgers RD, Rivkin SE, Von Hoff DD, Alberts DS. Mitoxantrone in epithelial carcinoma of the ovary: a Southwest Oncology Group Study. American Journal of Clinical Oncology — Cancer Clinical Trials 7: 499–501,1984

    Article  CAS  Google Scholar 

  • Hippe E, Clausen NAT, Gimsing P, Haedersdal C. Resistant multiple myeloma treated with mitoxantrone in combination with vincristine and prednisolone (NOP-regime). Correspondence. European Journal of Haematology 39: 88–89, 1987

    Article  PubMed  CAS  Google Scholar 

  • Ho AD, Del Valle F, Rückle R, Schwammborn G, Schlimock N, et al. Mitoxantrone combined with high dose cytarabine for refractory non-Hodgkin’s lymphoma. Effects of recombinant GM-CSF. Abstract 237. Investigational New Drugs 2: 408, 1989a

    Google Scholar 

  • Ho AD, Del Valle F, Ruckle H, Schwammborn J, Schlimok G, et al. Mitoxantrone and high-dose cytarabine as salvage therapy for refractory non-Hodgkin’s lymphoma. Cancer 64: 1388–1392, 1989b

    Article  PubMed  CAS  Google Scholar 

  • HoAD, Dörken B, Hunstein W. Treatment of refractory Hodgkin’s disease with mitoxantrone. Abstract P-22-30. 14th International Congress of Chemotherapy, Kyoto, p. 342, June 23- 28, 1985a

  • Ho AD, Del Valle F, Engelhard M, Hiddemann W, Ruckle H, et al. Mitoxantrone/high dose ara-C and recombinant human GM-CSF in the treatment of refractory non-Hodgkin’s lymphoma. A pilot study. Cancer 66: 423–430, 1990a

    Article  PubMed  CAS  Google Scholar 

  • Ho AD, Haas R, Wulf G, Knauf W, Ehrhardt R, et al. Activation of lymphocytes induced by recombinant human granulocyte-macrophage colony-stimulating factor in patients with malignant lymphoma. Blood 75: 203–212, 1990b

    PubMed  CAS  Google Scholar 

  • Ho AD, Lipp T, Ehninger G, Illiger H-J, Meyer P, et al. Combination of mitoxantrone and etoposide in refractory acute myelogenous leukemia — an active and well-tolerated regimen. Journal of Clinical Oncology 6: 213–217, 1988

    PubMed  CAS  Google Scholar 

  • Ho AD, Seither E, Ma DDF, Prentice HG. Mitozantrone-induced toxicity and DNA strand breaks in leukaemic cells. British Journal of Haematology 65: 51–55, 1987

    Article  PubMed  CAS  Google Scholar 

  • HoAD, Seither E, Prentice HG. Evaluation of DNA strand breaks and its subsequent repair in leukemic cells for predicting response to a DNA intercalating agent (mitoxantrone). Abstract S-65-4. International Congress of Chemotherapy, Kyoto, Japan, p. 228, 23–28 June, 1985b

  • Hoffmann W, Wandt S, Janson R, Seeber S. Klinische Erfahrungen mit der intraarteriellen, angiographisch gesteuerten Chemotherapie von Lebermetastasen. Tumor Diagnostik und Therapie 11: 111–115,1990

    Google Scholar 

  • Holmes FA, Yap H-Y, Esparza L, Buzdar AU, Hortobagyi GN, et al. Mitoxantrone, cyclophosphamide and 5-flourouracil in the treatment of hormonally unresponsive metastatic breast cancer. Seminars in Oncology 11 (Suppl, 1): 28–31, 1984

    PubMed  CAS  Google Scholar 

  • Hørding U, Rose C, Jakobsen K, Dirksen H. Mitoxantrone in advanced cervical carcinoma: a phase II study in patients not previously treated with chemotherapy. Cancer Treatment Reports 70: 1239–1240, 1986

    PubMed  Google Scholar 

  • Howson-Jan K, Claxton D, Brox A. VP-16/mitoxantrone in the treatment of refractory acute myelogenous leukaemia. In Bonadonna G (Ed.) Clinical progress of mitoxantrone. Royal Society of Medicine Services International Congress and Symposium Series No. 110, pp. 43–46, Royal Society of Medicine Services Limited, 1987

  • Hulhoven R, Dumont E, Harvengt C. Plasma kinetics of mitoxantrone in leukemic patients. Medical Oncology and Tumour Pharmacotherapy 1: 201–204, 1984

    CAS  Google Scholar 

  • Iatropoulos MJ. Anthracycline cardiomyopathy: predictive value of animal models. Cancer Treatment Symposia 3: 3–17, 1984

    Google Scholar 

  • Inoue K, Fujimoto S, Ogawa M. Antitumour efficacy of seventeen anticancer drugs in human breast cancer xenograft (MX-1) transplanted in nude mice. Cancer Chemotherapy and Pharmacology 10: 182–186, 1983

    Article  PubMed  CAS  Google Scholar 

  • Ito Y, Hoshino A, Ohara K, Kamiya O, Nagata K, et al. The effects of combination chemotherapy M-VEMFH including mitoxantrone (MXN) for advanced breast cancer. Abstract P-29-44. 14th International Congress of Chemotherapy, Kyoto, Japan, p. 377, 23–28 June 1985

  • James V, Chiccarelli F, Dougherty W, Hall C, Henderson B, et al. Preclinical toxicology studies on mitoxantrone and bisantrene. In Rozencweig M et al. (Eds) New anticancer drugs: mitoxantrone and bisantrene, pp. 47–69, Raven Press, New York, 1983

    Google Scholar 

  • Jamison JM, Krabill K, Flowers DG, Tsai C-C. Enhancement of the antiviral activity of poly r(A-U) by ametantrone and mitoxantrone. Life Sciences 46: 653–661, 1990

    Article  PubMed  CAS  Google Scholar 

  • Janmohammed R, Milligan DW. Mitoxantrone induced congestive heart failure in patients previously treated with anthracyclines. British Journal of Haematology 71: 292–293, 1989

    Article  PubMed  CAS  Google Scholar 

  • Jelliffe AM. A review of BNLI patients with non-Hodgkin’s lymphoma, and the place of novantrone with LEPP in the management of unfit patients. Proceedings of the 2nd UK Novantrone Symposium, pp. 95–105, 1986

  • Jensen PB, Vindeløv L, Roed H, Demant EJF, Sehested M, et al. In vitro evaluation of the potential of aclarubicin in the treatment of small cell carcinoma of the lung (SCCL). British Journal of Cancer 60: 838–844, 1989

    Article  PubMed  CAS  Google Scholar 

  • Johnson P. Intra-arterial administration of novantrone and its use in the treatment of hepatoma. Proceedings of the 2nd UK Novantrone Symposium, pp. 131–134, 1986

  • Johnson RK, Zee-Cheng RK-Y, Lee WW, Acton EM, Henry DW, et al. Experimental antitumor activity of aminoanthraquinones. Cancer Treatment Reports 63: 425–439, 1979

    PubMed  CAS  Google Scholar 

  • Jones L, Cotter FE, Lord D, Newland AC. Phase 2 study of mitozantrone in combination with chlorambucil and prednisolone for relapsed and refractory non-Hodgkins lymphoma. Hematological Oncology 8: 41–45, 1990

    Article  PubMed  Google Scholar 

  • Jones S, Gams R, Case D, Stein R, Stuart J, et al. Mitoxantrone in malignant lymphomas: results of a multi-centre phase II trial. Abstract. 3rd European Conference on Clinical Oncology and Cancer, Stockholm, p. 8, 1985a

  • Jones SE, Dean JC, Young LA, Salmon SE. The human tumor clonogenic assay in human breast cancer. Journal of Clinical Oncology 3: 92–97, 1985b

    PubMed  CAS  Google Scholar 

  • Juvekar AS, Chitnis MP, Advani SH. In vitro modulation of adriamycin and mitoxantrone cytotoxicity by hyperthermia and diazepam, in human chronic myeloid leukemia cells. Neoplasma 34: 199–204, 1987

    PubMed  CAS  Google Scholar 

  • Juvekar AS, Chitnis MP, Adwankar MK, Advani SH. Effect of mitoxantrone on human chronic myeloid leukemia cells in vitro, combined with hyperthermia. Neoplasma 33: 447–482, 1986

    Google Scholar 

  • Kaminer LS, Choi KE, Daley KM, Larson RA. Continuous infusion mitoxantrone in relapsed acute nonlymphocytic leukemia. Cancer 65: 2619–2623, 1990

    Article  PubMed  CAS  Google Scholar 

  • Kantarjian HM, Walters RL, Keating MJ, Estey EH, O’Brien S, et al. Mitoxantrone and high-dose cytosine arabinoside for the treatment of refractory acute lymphocytic leukemia. Cancer 65: 5–8, 1990

    Article  PubMed  CAS  Google Scholar 

  • Kantarjian HM, Walters RS, Keating MJ, Talpaz M, Andersson B, et al. Treatment of the blastic phase of chronic myelogenous leukemia with mitoxantrone and high-dose cytosine arabinoside. Cancer 62: 672–676, 1988

    Article  PubMed  CAS  Google Scholar 

  • Kaplan L, Volberding PA. Failure (and danger) of mitozantrone in AIDS-related Kaposi’s sarcoma. Correspondence. Lancet 2: 396, 1985

    Article  PubMed  CAS  Google Scholar 

  • Kappos L, Gold R, Künstler E, Rohrbach E, Heun R, et al. Mitoxantrone (Mx) in the treatment of rapidly progressive MS: a pilot study with serial gadolinium (Gd)-enhanced MRI. Abstract 539P. Neurology 40 (Suppl. 1): 261, 1990

    Google Scholar 

  • Kapuscinski J, Darzynkiewicz Z. Interactions of antitumor agents ametantrone and mitoxantrone (Novatrone) with double-stranded DNA. Biochemical Pharmacology 34: 4203–4213, 1985

    Article  PubMed  CAS  Google Scholar 

  • Kapuscinski J, Darzynkiewicz Z, Traganos F, Melamed MR. Interactions of a new antitumor agent, l,4-dihydroxy-5,8-bis[[2-[(2-hydroxyethyl)amino]-ethyl]amino]-9, 10-anthracenedione, with nucleic acids. Biochemical Pharmacology 30: 231–240,1981

    Article  PubMed  CAS  Google Scholar 

  • Kars A, Baltali K, Tekuzman G, Firat D, Alakavuklar M. Mitoxantrone plus tamoxifen vs tamoxifen alone in menopausal advanced breast cancer patients. Abstract 366. 6th Mediterranean Congress of Chemotherapy, Italy, p. 17, 1988

  • Kaufmann M, Manegold C, Schmid H, Kubli F. Phase-II study of mitoxantrone and prednimustine in advanced breast cancer. In Bonadonna G (Ed.) Clinical progress with mitoxantrone. Royal Society of Medicine Services International Congress and Symposium Series 110, pp. 17–25, Royal Society of Medicine Services Limited, 1987

  • Keller JW, Omura GA, Gams RA, Bartolucci AA. Weekly mitoxantrone therapy of Hodgkin’s disease, non-Hodgkin’s lymphoma, and chronic lymphocytic leukemia, A Southeastern Cancer Study Group trial. American Journal of Clinical Oncology — Cancer Clinical Trials 10: 194–195, 1987

    Article  CAS  Google Scholar 

  • Kharasch ED, Novak RF. Mitoxantrone and ametantrone inhibit hydroperoxide-dependent initiation and propagation reactions in fatty acid peroxidation. Journal of Biological Chemistry 260: 10645–10652, 1985

    PubMed  CAS  Google Scholar 

  • Khoury GG. Local tissue damage as a result of extravasation of mitozantrone. Correspondence. British Medical Journal 292: 802, 1986

    Article  Google Scholar 

  • Kimura I, Ohnoshi T, Masaoka T, Sampi K, Namba K. Mitoxantrone-containing combination chemotherapy for patients with non-Hodgkin’s lymphoma. (In Japanese) Japanese Journal of Cancer Chemotherapy 13: 3034–3039, 1986

    CAS  Google Scholar 

  • Knight WA, Von Hoff DD, Neidhart JA, Tranum BL, Fabian C, et al. Mitoxantrone in advanced breast cancer: a phase II trial of the Southwest Oncology Group. Investigational New Drugs 1: 181–184, 1983

    PubMed  Google Scholar 

  • Kober F, Heiss A, Keminger K, Depisch D. Chemotherapie hochmalings Schilddrusentumore. Wiener Klinische Wochenschrift 102:274–276,1990

    PubMed  CAS  Google Scholar 

  • Kokron O, Maca S. Mitoxantrone (Novantrone®) in treatment of inoperable non small cell lung cancer (NSCLC). Abstract P-22-29. 14th International Congress of Chemotherapy, Kyoto, p. 341, June 23–28, 1985

  • Kolodziejczyk P, Reszka K, Lown JW. Enzymatic oxidative activation and transformation of the antitumor agent mitoxantrone. Free Radical Biology and Medicine 5: 13–25, 1988

    Article  PubMed  CAS  Google Scholar 

  • Koppensteiner R, Minar E, Marosi L, Ehringer H. Survival following an extremely high-dose of mitoxantrone in a 73-year-old female with small cell bronchial carcinoma. Correspondence. Journal of Cancer Research and Clinical Oncology 114: 324, 1988

    Article  PubMed  CAS  Google Scholar 

  • Kowal CD, Bertino JR. Possible benefits of hyperthermia to chemotherapy. Cancer Research 39: 2285–2289, 1979

    PubMed  CAS  Google Scholar 

  • Kramer BS, Gams R, Birch R, Einhorn L, Buchanan R. Phase II evaluation of mitoxantrone in patients with bronchogenic carcinoma: a Southeastern Cancer Study Group trial. Cancer Treatment Reports 68: 1295–1296, 1984

    PubMed  CAS  Google Scholar 

  • Krehmeier C, Zühlsdorf M, Büchner Th, Hiddemann W. Synergistic cytotoxicity of cytosine arabinoside and mitoxantrone for K562 and CFU-GM. Haematology and Blood Transfusion 33: 129–132, 1990

    Article  PubMed  CAS  Google Scholar 

  • Krulder JWM, Haak HL. Mitoxantrone, VM-26, chlorambucil and prednisone in refractory non-Hodgkin’s lymphoma. Abstract. 4th International Symposium on Therapy of Acute Leukemias, Rome, p. 21, 1987

  • Kuhn K, Purea H, Selbach J, Westerhausen M. Treatment with locally applied mitoxantrone. Acta Medica Austriaca 16: 87–90, 1989

    PubMed  CAS  Google Scholar 

  • Kumar L, Kochipillai V. Mitoxantrone induced hyperpigmentation. New Zealand Medical Journal 103: 55, 1990

    PubMed  CAS  Google Scholar 

  • Lai K-H, Tsai Y-T, Lee S-D, Ng W-W, Teng H-C, et ai. Phase 11 study of mitoxantrone in unresectable primary hepatocellular carcinoma following hepatitis B infection. Cancer Chemotherapy and Pharmacology 23: 54–56, 1989

    Article  PubMed  CAS  Google Scholar 

  • Lakhani AK, Zuiable AG, Pollard CM, Milne A, Treleaven J, et al. Paraplegia after intrathecal mitozantrone. Correspondence. Lancet 2: 1393, 1986

    Article  PubMed  CAS  Google Scholar 

  • Landys KE. Mitoxantrone in combination with prednimustine in treatment of unfavorable non-Hodgkin lymphoma. Investigational New Drugs 6: 105–113, 1988

    Article  PubMed  CAS  Google Scholar 

  • Landys K, Borgstrom S, Andersson T, Noppa H. Mitoxantrone as a first-line treatment of advanced breast cancer. Investigational New Drugs 3: 133–137, 1985

    Article  PubMed  CAS  Google Scholar 

  • Laporte JP, Gorin NC, Lemonnier MP, Isnard F, Najman A. A new combination of two intercalating agents (mitoxantrone + daunomycin) in adult refractory acute leukemia: the DON protocol. Cancer Chemotherapy and Pharmacology 22: 344–346, 1988

    Article  PubMed  CAS  Google Scholar 

  • Larson RA, Daly KM, Choi KE, Han DS, Sinkule JA. A clinical and pharmacokinetic study of mitoxantrone in acute nonlymphocytic leukemia. Journal of Clinical Oncology 5: 391–397, 1987

    PubMed  CAS  Google Scholar 

  • Laster Jr WR, Witt MH, Schabel Jr FM. Therapeutic synergism (TS) of N-(4-(9-acridinylamino)-3-methoxyphenyl]methanesulfonamide (m-AMSA) or l,4-dihydroxy-5,8-bis [[2-[(2-hydroxyethyl)amino]ethyl]amino]-9,10-anthracenedione (DiOHA) plus cis-diamminedichloroplatinum (cis-DDPt) against P388/ 0 leukemia. Abstract 1086. Proceedings of the American Association of Cancer Research 21: 271, 1980

    Google Scholar 

  • Lathan B, Von Hoff DD, Elslager E. Use of a human tumor cloning system to evaluate analogs of methotrexate and mitoxantrone. Cancer Treatment Reports 68: 733–738, 1984

    PubMed  CAS  Google Scholar 

  • Launay M-C, Iliadis A, Richard B. Population pharmacokinetics of mitoxantrone performed by a NONMEM method. Journal of Pharmaceutical Sciences 78: 877–880, 1989

    Article  PubMed  CAS  Google Scholar 

  • Lawton F, Blackledge G, Mould J, Latief T, Watson R, et al. Phase II study of mitoxantrone in epithelial ovarian cancer. Cancer Treatment Reports 71: 627–629, 1987

    PubMed  CAS  Google Scholar 

  • Lawton FG, Redman CWE, Luesley DM, Chan KK, Blackledge G. Neoadjuvant (cytoreductive) chemotherapy combined with intervention debulking surgery in advanced, unresected epithelial ovarian cancer. Obstetrics and Gynecology 73: 61–65, 1989

    PubMed  CAS  Google Scholar 

  • Lawton PA, Ostrowski MJ, Young T, Spittle MF. Efficacy and toxicity of single agent chemotherapy in advanced breast carcinomas. Abstract. British Journal of Cancer 61; 177, 1990

    Google Scholar 

  • Lazzarino M, Morra E, Alessandrino EP, Orlandi E, Pagnucco G, et al. Mitoxantrone and etoposide: an effective regimen for refractory or relapsed acute myelogenous leukemia. European Journal of Haematology 43: 411–416, 1989

    Article  PubMed  CAS  Google Scholar 

  • Leiby JM, Unverfurth DV, Neidhart JA. High-dose mitoxantrone in metastatic breast cancer: a phase I-II trial. Cancer Treatment Reports 70: 899–901, 1986

    PubMed  CAS  Google Scholar 

  • Lejeune C, Tubiana N, Gastaut JA, Maraninchi D, Richard B, et al. High-dose cytosine arabinoside and mitoxantrone in previously-treated acute leukemia patients. European Journal of Haematology 44: 240–243, 1990

    Article  PubMed  CAS  Google Scholar 

  • LeMaistre CF, Herzig R. Mitoxantrone: potential for use in intensive therapy. Seminars in Oncology 17 (Suppl. 3): 43–48, 1990

    PubMed  CAS  Google Scholar 

  • Lenzhofer R, Rainer H, Schuster R, Dudczak R, Dittrich C. Mitoxantrone as a single agent and in combination with cyclo-phosphamide in metastasizing breast cancer. Abstract P-29-42. 14th International Congress of Chemotherapy, Kyoto, Japan, p. 377, 23–28 June 1985

  • Lenzhofer R, Rainer H, Schuster R, Pirker P, Dudczak R, et al. Mitoxantrone zur Erstbehandlung des metastasierten Mammakarzinoms. Wiener Klinische Wochenschrift 96: 319–326, 1984

    PubMed  CAS  Google Scholar 

  • Leonard RCF, Cornbleet MA, Kaye SB, Soukop M, White G, et al. Mitoxantrone versus doxorubicin in combination chemotherapy for advanced carcinoma of the breast. Journal of Clinical Oncology 5: 1056–1063, 1987

    PubMed  CAS  Google Scholar 

  • Lev L, Biran S, Chaitchik S, Brenner H, Robinson E, An Israeli National Study. Mitoxantrone, methotrexate, 5-flourouracil versus cyclophosphamide, methotrexate, 5-flourouracil as first line therapy in metastatic breast cancer. Abstract 175. Cancer Immunology and Immunotherapy 23 (Suppl.): A44, 1986

    Google Scholar 

  • Levi JA, Gill PG, Presgrave P. A phase II study of mitoxantrone in advanced gastric cancer. Investigational New Drugs 8: 305–306, 1990

    Article  PubMed  CAS  Google Scholar 

  • Levin M, Pandya KJ, Khandekar JD, Horton J, Glick JH, et al. Phase II study of mitoxantrone in advanced breast cancer: an Eastern Cooperative Oncology Group Pilot Study. Cancer Treatment Reports 68: 1511–1512, 1984

    PubMed  CAS  Google Scholar 

  • Levine S, Gherson J. Morphologic effects of mitoxantrone and a related anthracenedione on lymphoid tissues. International Journal of Immunopharmacology 8: 999–1007, 1986

    Article  PubMed  CAS  Google Scholar 

  • Levine S, Saltzman A. Regional suppression, therapy after onset and prevention of relapses in experimental allergic encephalomyelitis by mitoxantrone. Journal of Neuroimmunology 13: 175–181, 1986

    Article  PubMed  CAS  Google Scholar 

  • Leyden M, Cheng Z-M, Collins J, Russell I, Andrews J, et al. Mitoxantrone treatment in advanced breast cancer. Australian and New Zealand Journal of Surgery 54: 21–24, 1984

    Article  PubMed  CAS  Google Scholar 

  • Link H, Freund M, Diedrich H, Wilke H, Austein J, et al. Mitoxantrone, cytosine arabinoside, and VP-16 in 36 patients with relapsed and refractory acute myeloid leukemia. Haematology and Blood Transfusion 33: 322, 1990

    Article  PubMed  CAS  Google Scholar 

  • Loeffler T, Freund W. Pharmacokinetics of mitoxantrone intraperitoneal. Abstract 694. Proceedings of the American Association of Cancer Research 27: 175, 1986

    Google Scholar 

  • Longueville J. Mitoxantrone: review of effectiveness and side effects. Proceedings of the International Symposium on Senology, Belgium, pp. 343–363, 1985

  • Lorusso V, Brandi M, Berardi F, Pellecchia A, De Lena M. Ifosfamide e mitoxantrone nella terapia di salvataggio dei linfomi non-hodgkin (NHL). Abstract 324. Tumori 75 (Suppl. 4): 104, 1989

    Google Scholar 

  • Lown JW, Hanstock CC. High field H-NMR analysis of the 1: 1 intercalation complex of the antitumor agent mitoxantrone and the DNA duplex [d(CpGpCpG)]. Journal of Biomolecular Structure and Dynamics 2: 1097–1106, 1985

    Article  PubMed  CAS  Google Scholar 

  • Lown JW, Hanstock CC, Bradley RD, Scraba DG. Interactions of the antitumor agents mitoxantrone and bisantrene with deoxyribonucleic acids studied by electron microscopy. Molecular Pharmacology 25: 178–184, 1984

    PubMed  CAS  Google Scholar 

  • Lown JW, Morgan AR, Yen S-F, Wang Y-H, Wilson WD. Characteristics of the binding of the anticancer agents mitoxantrone and ametantrone and related structures to deoxyribonucleic acids. Biochemistry 24: 4028–4035, 1985

    Article  PubMed  CAS  Google Scholar 

  • Lu K, Savaraj N, Loo LT. Pharmacological disposition of 1,4-dihydroxy-5,8-bis([2-[(2-hydroxymethyl)amino]ethyl]amino)-9,10-anthracenedione dihydrochloride in the dog. Cancer Chemotherapy and Pharmacology 13: 63–66, 1984

    Article  PubMed  CAS  Google Scholar 

  • Lublin FD, Lavasa M, Viti C, Knobler RL. Suppression of acute and relapsing experimental allergic ericephalomyelitis with mitoxantrone. Clinical Immunology and Immunopathology 45: 122–128, 1987

    Article  PubMed  CAS  Google Scholar 

  • Manandhar M, Cheng M, Iatropoulos MJ, Noble JF. Genetic toxicology profile of the new antineoplastic drug mitoxantrone in the mammalian test systems. Arzneimittel-Forschung Drug Research 36: 1375–1379, 1986

    CAS  Google Scholar 

  • Marcellino LR, Bandini M, Chiappini L, Bizzarri M. Preliminary results with mitoxantrone therapy in primary liver cancer. Abstract 303. 6th Mediterranean Congress of Chemotherapy, Italy, p. 19, 1988

  • Marcellino LR, Bizzarri M. Mitoxantrone in advanced breast cancer refractory to previous Chemotherapie treatment. Abstract 430. 6th Mediterranean Congress of Chemotherapy, Italy, p. 26,vl988 Markman M, George M, Hakes T, Reichman B, Hoskins W, et al. Phase II trial of intraperitoneal mitoxantrone in the management of refractory ovarian cancer. Journal of Clinical Oncology 8: 146–150, 1990

    Google Scholar 

  • Marmor JB. Interactions of hyperthermia and chemotherapy in animals. Cancer Research 39: 2269–2276, 1979

    PubMed  CAS  Google Scholar 

  • Martoni A, Rani P, Ercolino L, Canova N, Pannuti F. Mitoxantrone, 5-fluorouracil and cyclophosphamide in advanced breast cancer. Chemioterapia 7: 345–349, 1988

    PubMed  CAS  Google Scholar 

  • Masaoka T, Shibata H, Oguma S, Nagai K, Kitani T, et al. A phase II study of mitoxantrone in acute leukemia. Investigational New Drugs 3: 197–201,1985

    Article  PubMed  CAS  Google Scholar 

  • Mattox DE, Clark GM, Balcerzak SP, O’Bryan RM, Oishi N, et al. Southwest Oncology Group study of mitoxantrone for treatment of patients with advanced squamous cell carcinoma of the head and neck. Investigational New Drugs 2: 405–497, 1984

    Article  PubMed  CAS  Google Scholar 

  • Mattox DE, Von Hoff DD, Balcerzak SP. Southwest Oncology Group study of mitoxantrone for treatment of patients with advanced adenoid cystic carcinoma of the head and neck. Investigational New Drugs 8: 105–107, 1990

    Article  PubMed  CAS  Google Scholar 

  • McDonald DB, Abu-Zahra H, Yoshida S, Binder H. Mitoxantrone and cyclophosphamide in advanced breast cancer: a pilot study. Seminars in Oncology 11 (Suppl. 1): 19–22, 1984a

    PubMed  CAS  Google Scholar 

  • McDonald DB, Abu-Zahra H, Yoshida S, Binder H. Novantrone and cyclophosphamide in advanced breast cancer. Abstract. New perspectives in chemotherapy: focus on Novantrone, Feb 1984, Toronto, p. 13, 1984b

  • McMillan AK, Goldstone AH, Linch DC, Gribben JG, Patterson KG, et al. High-dose chemotherapy and autologous bone marrow transplantation in acute myeloid leukemia. Blood 76: 480–488, 1990

    PubMed  CAS  Google Scholar 

  • Meloni G, De Fabritiis P, Pulsoni A, Sandrelli A, Giona F, et al. Results of two different conditioning regimens followed by ABMT in refractory acute lymphoblastic leukemia. Haematologica 74: 67–70, 1989

    PubMed  CAS  Google Scholar 

  • Mergenthaler H-G, Brühl P, Ehninger G, Heidemann E. Comparative in vitro toxicity of mitoxantrone and adriamycin in human granulocyte-macrophage progenitor cells. Cancer Chemotherapy and Pharmacology 20: 8–12, 1987

    Article  PubMed  CAS  Google Scholar 

  • Merkle E, Fuchs U, Bahr I, Wirtz PM, Tulusan AH, et al. Kombinationstherapie des metastasierten Mammakarzinoms mit Mitoxantron, Cyclophosphamid und 5-Fluorouracil. Tumor Diagnostik und Therapie 11: 162–166, 1990

    Google Scholar 

  • Mertelsmann R, Fuhr HG, Burkert M, Herrmann F. Mitoxantrone and high-dose cytosine-arabinoside for remission induction in refractory and previously untreated acute non-lymphoblastic leukemia. Abstract. 4th International Symposium on Therapy on Acute Leukemias, Rome, p. 23, 1987

  • Milpied N, Gisselbrecht C, Harousseau J-L, Sebbon C, Witz F, et al. Successful treatment of adult acute lymphoblastic leukemia after relapse with prednisone, intermediate-dose cytarabine, mitoxantrone, and etoposide (PAME) chemotherapy. Cancer 66: 627–631, 1990

    Article  PubMed  CAS  Google Scholar 

  • Mimnaugh EG, Trush MA, Ginsburg E, Gram TE. Differential effects of anthracycline drugs on rat heart and liver microsomal reduced nicotinamide adenine dinucleotide phosphate-dependent lipid peroxidation. Cancer Research 42: 3574–3582, 1982

    PubMed  CAS  Google Scholar 

  • Miser JS, Malspeis L, Staubus AE, Guest RT, Neidhart JA. Plasma pharmacokinetics of mitoxantrone in pédiatrie patients. Abstract 521. Proceedings of the American Association of Cancer Research, p32, 1983

  • Misset J-L, Metz R, Gil-Delgado M, Keiling R, Cappelaere P, et al. Mitoxantrone combined with vincristine, cyclophosphamide and fluorouracil for advanced breast cancer: a study of short-term response rate. Anticancer Research 7: 737–740, 1987

    PubMed  CAS  Google Scholar 

  • Moore JO, Olsen GA. Mitoxantrone in the treatment of relapsed and refractory acute leukemia. Seminars in Oncology 11 (Suppl. 1): 41–46, 1984

    PubMed  CAS  Google Scholar 

  • Moules IK. Clinical tolerance of novantrone. Proceedings of the 2nd UK Novantrone Symposium, pp. 145–151, 1986

  • Mouridsen HT, Andersson M, Pedersen L. Combined cytotoxic and endocrine treatment of postmenopausal patients with advanced breast cancer: preliminary results of a phase II study of the combination of prednimustine, novantrone, methotrexate, 5-fluorouracil, and tamoxifen. Seminars in Oncology 13 (Suppl. 1): 39–41, 1986

    PubMed  CAS  Google Scholar 

  • Mouridsen HT, Cornbleet M, Stuart-Harris R, Smith I, Coleman R, et al. Mitoxantrone as first-line chemotherapy in advanced breast cancer: results of a collaborative European study. Investigational New Drugs 3: 139–148, 1985

    Article  PubMed  CAS  Google Scholar 

  • Mouridsen HT, Rose C, Nooy MA, van Oosterom AT. Mitoxantrone as first line cytotoxic therapy in advanced breast cancer: preliminary results of a phase II study. Cancer Treatment Reviews 10 (Suppl. B): 47–52, 1983

    Article  PubMed  Google Scholar 

  • Muggia FM, Carter SK. Malignant diseases. In Speight TM (Ed.) Avery’s drug treatment. Principles and practice of clinical pharmacology and therapeutics, 3rd ed., pp. 1023–1077, ADIS Press, New Zealand, 1987

    Google Scholar 

  • Mulder POM, Sleijfer DT, Willemse PHB, de Vries EGE, Uges DRA, et al. High-dose cyclophosphamide or melphalan with excalating doses of mitoxantrone and autologous bone marrow transplantation for refractory solid tumors. Cancer Research 49: 4654–4658, 1989

    PubMed  CAS  Google Scholar 

  • Müller H, Aigner KR. Die isolierte Beckenperfusion (IPP) zur Behandlung primär inoperabler Beckentumaren. Klinische une pharmakokinetische Ergebnisse. Tumor Diagnostik und Therapie 11: 175–179, 1990

    Google Scholar 

  • Murdock KC, Child RG, Fabio PF, Angier RB, Wallace RE, et al. Antitumor agents. I. l,4-bis[(aminoalkyl)amino]-9,10-anthracenediones. Journal of Medicinal Chemistry 22: 1024–1030, 1979

    Article  PubMed  CAS  Google Scholar 

  • Murillo E, Moreno JA, Duque A, Guillem V, Herranz C, et al. Randomized comparison of cyclosphosphamide — mitoxantrone (CN) vs. cyclophosphamide — doxorubicin (CA) as first line therapy in advanced breast cancer. Abstract 637. 3rd European Conference Clinical Oncology and Cancer, Stockholm, p. 166, 1985

    Google Scholar 

  • Murray M, Coppin C, MacDermaid T. Mitoxantrone as first line chemotherapy for metastatic prostate cancer: preliminary phase II results. Abstract S-l-6. 14th International Congress of Chemotherapy, Kyoto, Japan, June 23–25, p. 97, 1985

  • Murray EF, Wallace RE. CL 232,315 (NSC 301739) 1,4-dihydroxy-5,8-bis[[2-[(2-hydroxyethyl)amino]-ethyl]amino]9,10-anthracenedione dihydrochloride: a novel antitumor agent. In Anthracyclines: current status and new developments, pp. 397–402, Academic Press Inc., New York, USA, 1980

  • Musch E, Mackes KG, Bode U, Peiss J, Werner A. Intrapleurale Applikation von Mitoxantron zur Behandlung ausgedehnter Pleuraergüsse bei metastasiertem Mamma-Ca. Praxis Klinische Pneumologie 41: 752–753, 1987

    Google Scholar 

  • Musch E, Mackes KG, Hartlapp JH, Peis J, Ammon J. Intrapleural mitoxantrone for treatment of malignant pleural effusion in metastatic breast cancer. Abstract 132. Blut 53: 205–206, 1986

    Google Scholar 

  • Musch E, Paar WD, Hoffmann B, Seitzer D, Chemassani A, et al. Intrapleurale Instillation von Mitoxantron zur Palliativ-Therapie maligner Pleuraergüsse. Tumor Diagnostik und Therapie 10: 64–71, 1989

    Google Scholar 

  • Muss HB, Bundy BN, Adcock L, Beecham J. Mitoxantrone in the treatment of advanced uterine sarcoma. A phase II trial of the Gynecologic Oncology Group. American Journal of Clinical Oncology — Cancer Clinical Trials 13: 32–34, 1990

    Article  CAS  Google Scholar 

  • Muss HB, Bundy BN, DiSaia PJ, Ehrlich CE. Mitoxantrone for carcinoma of the endometrium: a phase II trial of the Gynecologic Oncology Group. Cancer Treatment Reports 71: 217–218, 1987

    PubMed  CAS  Google Scholar 

  • Muss HB, Bundy BN, Christopherson WA. Mitoxantrone in the treatment of advanced vulvar and vaginal carcinoma. A Gynecologic Oncology Group study. American Journal of Clinical Oncology 12(2): 142–144, 1989

    Article  PubMed  CAS  Google Scholar 

  • Muss HB, Ehrlich CE, Asbury R, Graham J, Bundy B. Mitoxantrone (NSC-301739) in patients with advanced ovarian carcinoma. A phase II study of the Gynecologic Oncology Group. American Journal of Clinical Oncology 7: 737–739, 1984

    Article  PubMed  CAS  Google Scholar 

  • Muss HB, Sutton G.P, Bundy B, Hatch KD. Mitoxantrone (NSC 301739) in patients with advanced cervical carcinoma. A phase II study of the Gynecologic Oncology Group. American Journal of Clinical Oncology — Cancer Clinical Trials 8: 312–315, 1985

    Article  CAS  Google Scholar 

  • Nachtman JP, Roginski ET, Banning JW, Wormser HC, Abramson HN, et al. DNA binding, cardiac Superoxide production and cytotoxicity of daunomycin analogs. Research Communications in Chemical Pathology and Pharmacology 47: 73–83, 1985

    PubMed  CAS  Google Scholar 

  • Neidhart JA, Gochnour D, Roach R, Hoth D, Young D. A comparison of mitoxantrone and doxorubicin in breast cancer. Journal of Clinical Oncology 4: 672–677, 1986

    PubMed  CAS  Google Scholar 

  • Nelson EM, Tewey KM, Liu LF. Mechanism of antitumor drug action: poisoning of mammalian DNA topoisomerase II on DNA by 4′-(9-acridinylamino)-methanesulfon-m-anisidide. Proceedings of the National Academy of Science 81: 1361–1365, 1984

    Article  CAS  Google Scholar 

  • Neri B, Cini-Neri G, D’Alterio M. Effect of anthracyclines and mitoxantrone on oxygen uptake and ATP intracellular concentration in rat heart slices. Biochemical and Biophysical Research Communications 125: 954–960, 1984

    Article  PubMed  CAS  Google Scholar 

  • Nishio A, DeFeo F, Cheng CC, Uyeki EM. Sister-chromatid exchange and chromosomal aberrations by DHAQ and related anthraquinone derivatives in Chinese hamster ovary cells. Mutation Research 101: 77–86, 1982

    Article  PubMed  CAS  Google Scholar 

  • Nishio A, Uyeki EM. Cellular uptake and inhibition of DNA synthesis by dihydroxyanthraquinone and two analogues. Cancer Research 43: 1951–1956, 1983

    PubMed  CAS  Google Scholar 

  • Northcott M, Sewell G, Allsopp M, Rowland CG. Pharmacokinetic studies on mitozantrone in prolonged continuous infusion regimens. Abstract. British Journal of Cancer 61: 536, 1990

    Google Scholar 

  • Nortier JWR, Neijt JP, Bleeker PA, Meeuwissen OJATh, van Kessel D, et al. Mitoxantrone, methotrexate, and 5-fluorouracil (MMF) in hormone-refractory advanced breast cancer. Netherlands Journal of Medicine 35: 225–231, 1989

    PubMed  CAS  Google Scholar 

  • Novak RF, Kharasch ED. Mitoxantrone: propensity for free radical formation and lipid peroxidation — implications for cardiotoxicity. Investigational New Drugs 3: 95–99, 1985

    Article  PubMed  CAS  Google Scholar 

  • O’Brien MER, Eccles DM, Allen SG, Knight G, Rodger A, et al. Mitozantrone (M) and prednimustine (P) in advanced breast cancer (BC). Abstract. British Journal of Cancer 60: 457, 1989

    Google Scholar 

  • Ogawa M. Phase II trials of mitoxantrone in Japan. Abstract WS-13-3. 14th International Congress of Chemotherapy, Kyoto, June 23–28, p. 57, 1985

  • Ohnoshi T, Hayashi K, Ueno K, Murashima M, Tada A, et al. Diffuse non-Hodgkin’s lymphoma. (In Japanese) Japanese Journal of Hematology 30(8): 1201–1204, 1989

    CAS  Google Scholar 

  • Ohnoshi T, Hayashi K, Ueoka H, Yamane T, Ueno K, et al. Salvage chemotherapy for non-Hodgkin’s lymphoma with a combination of mitoxantrone, etoposide, cisplatin, and prednisolone. Cancer Treatment Reports 71: 639–641, 1987

    PubMed  CAS  Google Scholar 

  • Ohnuma T, Arkin H, Holland JF. Effects of cell density on drug-induced cell kill kinetics in vitro (inoculum effect). British Journal of Cancer 54: 415–421, 1986

    Article  PubMed  CAS  Google Scholar 

  • OKunewick JP, Buffo MJ, Kociban DL. Comparative toxicity of mitoxantrone and doxorubicin on hematopoietic stem cells. Experimental Hematology 13 (Suppl. 16): 23–30, 1985

    PubMed  CAS  Google Scholar 

  • Osborae CK, Cowan JD, Neidhart JA, Loveless H, Von Hoff DD, et al. The Southwest Oncology Group randomized trial of Novantrone®, Adriamycin®, and bisantrene in advanced breast cancer. Proceedings of the Symposium on the Current Status of Novantrone, pp. 55–58, Mar 21–24, 1985

  • Osborne CK, Drelichman A, Von Hoff DD, Crawford ED. Mitoxantrone: modest activity in a phase II trial in advanced prostate cancer. Cancer Treatment Reports 67: 1133–1135, 1983

    PubMed  CAS  Google Scholar 

  • Osswald H, Youssef M. Overadditive synergism between the intercalators mitoxantrone and lucanthone in advanced L 1210 and P 388 leukemia. Cancer Research and Clinical Oncology 111: 137–140, 1986

    Article  PubMed  CAS  Google Scholar 

  • Ostrowski MJ. Single agent study of novantrone in breast cancer. Proceedings of the 2nd UK Novantrone Symposium, pp. 57–63, 1986

  • Pacelli R, Scala S, Iaffaioli RV, Pepe S, Tagliaferri P, et al. Dati prelinari sull’attivatá in vitro dell’a2r IFN e del mitoxantrone su linee cellulane tumorali umane resistenti alia doxorubicina. Abstract 465. Tumori 75 (Suppl. 4): 158, 1989

    Google Scholar 

  • Paciucci PA, Crown JC, Holland JF. Mitoxantrone, vincristine, and dexamethasone in patients with refractory lymphoma. American Journal of Clinical Oncology — Cancer Clinical Trials 12: 327–331, 1989

    Article  CAS  Google Scholar 

  • Paciucci PA, Cuttner J, Holland JF. Mitoxantrone as a single agent and in combination chemotherapy in patients with refractory acute leukemia. Seminars in Oncology 11 (Suppl. 1): 36–40, 1984

    PubMed  CAS  Google Scholar 

  • Paciucci PA, Cuttner J, Holland JF. Sequential intermediate-dose cytosine arabinoside and mitoxantrone for patients with relapsed and refractory acute myelocytic leukemia. American Journal of Hematology 35: 22–25, 1990a

    Article  PubMed  CAS  Google Scholar 

  • Paciucci PA, Davis RB, Holland JF, Martelo O, Schiffer CA. Mitoxantrone and constant infusion etoposide for relapsed and refractory acute myelocytic leukemia. American Journal of Clinical Oncology Cancer Clinical Trials 13: 516–519, 1990b

    Article  CAS  Google Scholar 

  • Paciucci PA, Dutcher JP, Cuttner J, Strauman JJ, Wiernik PH, et al. Mitoxantrone and Ara-C in previously treated patients with acute myelogenous leukemia. Leukemia 1: 565–567, 1987

    PubMed  CAS  Google Scholar 

  • Palmieri RN, De Sena G, Cimmino L, Gridelli C, Incoronato P, et al. Il mitoxantrone nel trattomento deU’epatocarcinoma inoperable. Abstract 93. Tumori 75 (Suppl. 4): 35, 1989

    Google Scholar 

  • Periti P, Pannuti F, Robustelli della Cuna G, De Lena M, Pellegrini A, et al. First-line combination chemotherapy with mitoxantrone, cyclophosphamide and 5-fluorouracil in advanced breast cancer. In Bonadonna G (Ed.) Clinical progress with mitoxantrone. Royal Society of Medicine Services International Congress and Symposium Series 110, pp. 9–16, Royal Society of Medicine Services Limited, 1987

  • Periti P, Robustelli della Cuna G, Pannuti F, Mazzei T, Preti P, et al. First-line combination chemotherapy with mitoxantrone and cyclophosphamide in advanced breast cancer. Investigational New Drugs 3: 167–171, 1985

    Article  PubMed  CAS  Google Scholar 

  • Perkins WE, Schroeder RL, Carrano RA, Imondi AR. Myocardial effects of mitoxantrone and doxorubicin in the mouse and guinea pig. Cancer Treatment Reports 68: 841–847, 1984

    PubMed  CAS  Google Scholar 

  • Peters FTM, Beijnen JH, ten Bokkei Huinink WW. Mitoxantrone extravasation injury. Cancer Treatment Reports 71: 992–993, 1987

    PubMed  CAS  Google Scholar 

  • Phillips JK, Spearing RL. Resistant multiple myeloma treated with mitozantrone in combination with vincristine and dexamethasone (MOD). Correspondence. European Journal of Haematology 40: 378–379, 1988

    Article  PubMed  CAS  Google Scholar 

  • Plumbridge TW, Knight V, Patel KL, Brown JR. Mechanism of DNA-binding of some aminoalkylamino-derivatives of anthraquinone and naphthacenequinone. Journal of Pharmacy and Pharmacology 32: 78–80, 1980

    Article  PubMed  CAS  Google Scholar 

  • Poirier TI. Mitoxantrone. Drug Intelligence and Clinical Pharmacy 20: 97–105, 1986

    PubMed  CAS  Google Scholar 

  • Polverini PJ, Novak RF. Inhibition of angiotensin by the anti-neoplastic agents mitoxantrone and bisantrene. Biochemical and Biophysical Research Communications 140: 901–907, 1986

    Article  PubMed  CAS  Google Scholar 

  • Posner LE, Dukart G, Golberg J, Bernstein T, Cartwright K. Mitoxantrone: an overview of safety and toxicity. Investigational New Drugs 3: 123–132, 1985

    Article  PubMed  CAS  Google Scholar 

  • Possinger K, Goldmann U, Jaspers L, Sauer H, Wilmanns W. First-line treatment with vincristine (V), mitoxantrone (M) and cyclophosphamide (C) in patients with advanced breast cancer. Abstract S-65-8. 14th International Congress on Chemotherapy, Kyoto, 23–28 June, p. 228, 1985

  • Powles TJ, Ashley SE, Forgeson GV, O’Keeffe AP, Richards LJ, et al. Treatment of advanced breast cancer with mitomycin-C, mitoxantrone and methotrexate (3M) compared to vincristine, anthracycline and cyclophosphamide (VAC). In Bonadonna G. (Ed.) Clinical progress with mitoxantrone. Royal Society of Medicine Services International Congress and Symposium Series 110, pp. 1–7, Royal Society of Medicine Services Limited, 1987

  • Pratt CB, Vietti TJ, Etcubanas E, Sexauer C, Krance RA, et al. Novantrone for childhood malignant solid tumors. A pediatric oncology group phase II study. Investigational New Drugs 4: 43–48, 1986

    PubMed  CAS  Google Scholar 

  • Prentice HG, Robbins G, Ma DDF, Ho AD. Mitoxantrone in relapsed and refractory acute leukemia. Seminars in Oncology 11 (Suppl. 1): 32–35, 1984

    PubMed  CAS  Google Scholar 

  • Presant CA, Gams R, Bartolucci A, Southeastern Cancer Study Group. Mitoxantrone in malignant melanoma. Cancer Treatment Reports 68: 903–905, 1984a

    PubMed  CAS  Google Scholar 

  • Presant CA, Gams R, Bartolucci AA, Southeastern Cancer Study Group. Treatment of metastatic sarcomas with mitoxantrone. Cancer Treatment Reports 68: 813–814, 1984b

    PubMed  CAS  Google Scholar 

  • Pronzato P, Ardizzoni A, Conte PF, Gulisano M, Lionetto R, et al. A phase II study of mitoxantrone in advanced breast cancer. Chemioterapia 5: 150–153, 1986

    PubMed  CAS  Google Scholar 

  • Quigley M, Brada M, Heron C, Horwich A. Severe lung toxicity with a weekly low dose chemotherapy regimen in patients with non-Hodgkin’s lymphoma. Hematological Oncology 6: 319–324, 1988

    Article  PubMed  CAS  Google Scholar 

  • Quirt I, Eisenhauer E, Bramwell V, Knowling M, Grafton C, et al. Phase II study of mitoxantrone in untreated and previously minimally treated patients with metastatic soft tissue sarcomas. Cancer Treatment Reports 71: 1109–1110, 1987

    PubMed  CAS  Google Scholar 

  • Raghavan D, Coates A, Friedlander M, Woods RL, Levi J, et al. Mitoxantrone: progress in a phase II trial in Sydney, Australia. Abstract. Proceedings of the American Society of Clinical Oncology 1: 10, 1982

    Google Scholar 

  • Rees GJG. The comparative toxicity of epirubicin and novantrone. Proceedings of the 2nd UK Novantrone Symposium, pp. 65–67, 1986

  • Reszka K, Hartley JA, Kolodziejczyk P, Lown JW. Interaction of the peroxidase-derived metabolite of mitoxantrone with nucleic acids. Evidence for covalent binding of l4 C-labeled drug. Biochemical Pharmacology 38: 4253–4260, 1989

    Article  PubMed  CAS  Google Scholar 

  • Reymann A, Arps H, Dietel M, Schaefer B, Woermann C. Reduced mitoxantrone contents in a mitoxantrone-resistant gastric carcinoma cell line unrelated to the multidrug-resistance phenotype. Abstract 162. Naunyn-Schmiedeberg’s Archives of Pharmacology 341 (Suppl): R41, 1990

    Google Scholar 

  • Richardson CL, Roboz J, Holland JF. Competitive fluorescence polarization study of the binding of l,4-dihydroxy-5,8-bis[[2-[(2-hydroxyethyl) amino]ethyl]amino] 9-10-anthracenedione to DNA. Research Communications in Chemical Pathology and Pharmacology 27: 497–506, 1980

    PubMed  CAS  Google Scholar 

  • Ridge SC, Sloboda AE, McReynolds RA, Levine S, Oronsky AL, et al. Suppression of experimental allergic encephalomyelitis by mitoxantrone. Clinical Immunology and Immunopathology 35: 35–42, 1985

    Article  PubMed  CAS  Google Scholar 

  • Ritter J, Creutzig U, Henze G, Jürgens H, Bode U, et al. Hochdosiertes ARA-C in Kombination mit Mitoxantron bei der Therapie der AML im Kindesalter. Erste Ergebnisse der AML-Rezidivstudie BFM-85. Onkologie 10: 24–27, 1987

    Article  PubMed  CAS  Google Scholar 

  • Roberts RA, Cress AE, Dalton WS. Persistent intracellular binding of mitoxantrone in a human colon carcinoma cell line. Biochemical Pharmacology 38: 4283–4290, 1989

    Article  PubMed  CAS  Google Scholar 

  • Robertson JFR, Williams MR, Todd JH, Blarney RW. Mitoxantrone — a useful palliative therapy in advanced breast cancer. American Journal of Clinical Oncology — Cancer Clinical Trials 12: 393–396, 1989

    Article  CAS  Google Scholar 

  • Roboz J, Richardson CL, Holland JF. Comparison of the interaction of antineoplastic aminoanthraquinone analogs with DNA using competitive fluorescence polarization. Life Sciences 31: 25–30, 1982

    Article  PubMed  CAS  Google Scholar 

  • Robustelli della Cuna G, Pavesi L, Preti P, Baroni M. Mitoxantrone in advanced solid tumors: status of the art and perspectives. New Trends in the Therapy of Leukaemia and Lymphoma 3: 77–84, 1988

    Google Scholar 

  • Roninson IB, Chin JE, Choi K, Gros P, Housman DE, et al. Isolation of human mdr DNA sequences amplified in multidrug-resistant KB carcinoma cells. Proceedings of the National Academy of Science 83: 4538–4542, 1986

    Article  CAS  Google Scholar 

  • Roos G. Mitoxantrone sensitivity of human hematopoietic cell lines. Leukemia Research 11: 519–524, 1987

    Article  PubMed  CAS  Google Scholar 

  • Rosenberg LJ, Hittelman WN. Direct and indirect clastogenic activity of anthracenedione in Chinese hamster ovary cells. Cancer Research 43: 3270–3275, 1983

    PubMed  CAS  Google Scholar 

  • Runge H-M, Meerpohl HG, Pfleiderer A. Mitoxantrone therapy of advanced adenocarcinoma of the endometrium: a phase II trial. Onkologie 12: 102–113, 1989

    Article  PubMed  CAS  Google Scholar 

  • Safa AR, Ballou RJ, Tseng MT. Growth and ultrastructural responses of T-47D human breast tumor cells to treatment with mitoxantrone. Cancer Detection and Prevention 8: 455–464, 1985

    PubMed  CAS  Google Scholar 

  • Safa AR, Chegini N, Tseng MT. Influence of mitoxantrone on nucleic acid synthesis on the T-47D breast tumor cell line. Journal of Cellular Biochemistry 22: 111–120, 1983

    Article  PubMed  CAS  Google Scholar 

  • Salmon SE, Meyskens Jr FL, Alberts DS, Soehnlen B, Young L. New drugs in ovarian cancer and malignant melanoma: in vitro phase II screening with the human tumor stem cell assay. Cancer Treatment Reports 65: 1–2, 1981

    PubMed  CAS  Google Scholar 

  • Samir Motawy M, Salfiti R, Khalifa F, Fayyaz S, Baker H. Experience with combinations containing mitoxantrone in the treatment of adult acute leukemias. Journal of Chemotherapy 1: 123–127, 1989

    PubMed  CAS  Google Scholar 

  • Sampi K, Honda T, Hayashi Y, Hattori M. Phase II study of mitoxantrone in patients with hematological malignancy. (In Japanese) Japanese Journal of Cancer Chemotherapy 10: 1538–1539, 1983

    CAS  Google Scholar 

  • Sampi K, Ogawa M, Kimura I, Ohnoshi T, Yamada K, et al. Phase II trial of mitoxantrone in patients with relapsed and refractory acute leukemia. (In Japanese) Japanese Journal of Cancer Chemotherapy 13: 3021–3027, 1986

    CAS  Google Scholar 

  • Sanz MA, Martinez J, Borrego D, Martin-Aragonés G, Lorenzo I, et al. High-dose cytosine arabinoside and mitoxantrone in high-risk acute nonlymphoblastic leukemia. Seminars in Oncology 14 (Suppl. 1): 18–20, 1987

    PubMed  CAS  Google Scholar 

  • Sarosdy MF, Lamm DL, Radwin HM, Von Hoff DD. Clonogenic assay and in vitro chemosensitivity testing of human urologic malignancies. Cancer 50: 1332–1338, 1982

    Article  PubMed  CAS  Google Scholar 

  • Satyamoorthy K, Chitnis MP, Pradhan SG, Advani SH. Modulation of mitoxantrone cytotoxicity by verapamil in human chronic myeloid leukemia cells. Oncology 46: 128–131, 1989

    Article  PubMed  CAS  Google Scholar 

  • Savaraj N, Lu K, Manuel V, Loo TL. Pharmacology of mitoxantrone in cancer patients. Cancer Chemotherapy and Pharmacology 8: 113–117, 1982

    Article  PubMed  CAS  Google Scholar 

  • Schabel Jr FM, Corbett TH, Griswold Jr DP, Laster Jr WR, Trader MW. Therapeutic activity of mitoxantrone and ametantrone against murine tumors. Cancer Treatment Reviews 10 Suppl. B): 13–21, 1983a

    Article  PubMed  Google Scholar 

  • Schabel Jr FM, Skipper HE, Trader MW, Brockman RW, Laster Jr WR, et al. Drug control of Ara-C-resistant tumor cells. Medical and Pédiatrie Oncology (Suppl. 1): 125–148, 1982

  • Schabel Jr FM, Skipper HE, Trader MW, Laster Jr WR, Griswold Jr DP, et al. Establishment of cross-resistance profiles for new agents. Cancer Treatment Reports 67: 905–922, 1983b

    PubMed  Google Scholar 

  • Schlumberger M, Parmentier C. Phase II evaluation of mitoxantrone in advanced non-anaplastic thyroid cancer. Bulletin du Cancer 76: 403–406, 1989

    PubMed  CAS  Google Scholar 

  • Schneider T, Kupiec-Wezlinski JW, Towpik E, Kang BS, Durr FE, et al. Mitoxantrone — an immunosuppressive agent potentially useful in the organ transplantation. Abstract 7431. Federation Proceedings 44: 1681, 1985

    Google Scholar 

  • Schroeder M, Donhuijsen-Ant R, Westerhausen M. 5-Fluorouracil plus mitoxantrone in the treatment of advanced colorectal cancer initial experiences. Abstract 145. Blut 53: 211, 1986

    Google Scholar 

  • Schulman P, VanEcho D, Budman D, Ferrari A, Marks S, et al. Phase II trial of mitoxantrone (DHAD NSC 301739) in blastic phase in chronic myelogenous leukemia (B-CML). Abstract 558. Blood 60 (Suppl. 1): 158A, 1982

    Google Scholar 

  • Shenkenberg TD. Mitoxantrone and hepatic toxicity. Correspondence. Annals of Internal Medicine 105: 806, 1986

    Google Scholar 

  • Shenkenberg TD, Von Hoff DD. Mitoxantrone: a new anticancer drug with significant clinical activity. Annals of Internal Medicine 105: 67–81, 1986a

    PubMed  CAS  Google Scholar 

  • Shenkenberg TD, Von Hoff DD. Possible mitoxantrone-induced amenorrhea. Cancer Treatment Reports 70: 659, 1986b

    PubMed  CAS  Google Scholar 

  • Shepherd FA, Evans WK, Blackstein ME, Fine S, Mullis B. Hepatic arterial infusion (HAI) of mitoxantrone (MIT) in the treatment of primary hepatocellular carcinoma (HCG). Abstract S-70-10. 14th International Congress of Chemotherapy, Kyoto, Japan, 23–28 June, p. 239, 1985

  • Shpall EJ, Jones RB, Holland JF, Bhardwaj S, Paciucci PA, et al. Intensive single-agent mitoxantrone for metastatic breast cancer. Journal of the National Cancer Institute 80: 204–208, 1988

    Article  PubMed  CAS  Google Scholar 

  • Siegal T, Melamed E, Sandbank U, Catane R. Early and delayed neurotoxicity of mitoxantrone and doxorubicin following subarachnoid injection. Journal of Neuro-Oncology 6: 135–140, 1988

    Article  PubMed  CAS  Google Scholar 

  • Siegert W, Hiddemann W, Koppensteiner R, Büchner T, Essink M. et al. Accidental overdose of mitoxantrone in three patients. Medical Oncology and Tumor Pharmacotherapy 6: 275–278, 1989

    PubMed  CAS  Google Scholar 

  • Silver R, Case D, Jones S, Gams R, Stein R, et al. Novantrone™ mitoxantrone in the treatment of non-Hodgkin’s lymphoma: a phase II study. Abstract WS-13-7. 14th International Congress of Chemotherapy, Kyoto, Japan, 23–28 June, p. 57, 1985

  • Slater AJ, Green JA for the Mersey Breast Group. Mitozantrone or doxorubicin with vincristine and cyclophosphamide (VNC vs VAC) in the treatment of advanced breast cancer. Abstract. British Journal of Cancer 58: 264, 1988

    Google Scholar 

  • Sloboda AE, Oronsky AL, Kerwar SS. Studies of the effect of mitoxantrone on adjuvant induced arthritis in rats. Clinical Immunology and Immunopathology 40: 236–243, 1986

    Article  PubMed  CAS  Google Scholar 

  • Smalley R, Gams R. Phase II study of mitoxantrone in patients with metastatic breast carcinoma: a Southeastern Cancer Study Group project. Cancer Treatment Reports 67: 1039–1040, 1983

    PubMed  CAS  Google Scholar 

  • Smith IE. Mitoxantrone (novantrone): a review of experimental and early clinical studies. Cancer Treatment Reviews 10: 103–115, 1983

    Article  PubMed  CAS  Google Scholar 

  • Smith IE, Stuart-Harris R, Pavlidis N, Bozek T. Mitoxantrone (Novantrone) as single agent and in combination chemotherapy in the treatment of advanced breast cancer. Cancer Treatment Reviews 10 (Suppl. B): 37–40, 1983

    Article  PubMed  Google Scholar 

  • Smyth JF, Cornbleet MA, Stuart-Harris RC, Smith IE, Coleman RE, et al. Mitoxantrone as first-line chemotherapy for advanced breast cancer: results of a European Collaborative Study. Seminars in Oncology 11 (Suppl. 1): 15–18, 1984

    PubMed  CAS  Google Scholar 

  • Smyth JF, Macpherson JS, Warrington PS, Leonard RCF, Wolf CR. The clinical pharmacology of mitozantrone. Cancer Chemotherapy and Pharmacology 17: 149–152, 1986

    Article  PubMed  CAS  Google Scholar 

  • Sonneveld P, Michiels JJ. Full dose chemotherapy in elderly patients with non-Hodgkin’s lymphoma: a feasibility study using a mitoxantrone containing regimen. British Journal of Cancer 62: 105–108, 1990

    Article  PubMed  CAS  Google Scholar 

  • Sparano BM, Gordon G, Hall C, Iatropoulos MJ, Noble JF. Safety assessment of a new anticancer compound, mitoxantrone, in beagle dogs: comparison with doxorubicin. II. Histologie and ultrastructural pathology. Cancer Treatment Reports 66: 1145–1158, 1982

    PubMed  CAS  Google Scholar 

  • Stewart DJ. A randomized comparison of cyclophosphamide, novantrone and 5-fluorouracil versus cyclophosphamide, doxorubicin and 5-fluorouracil in advanced breast cancer. Abstract. New perspectives in chemotherapy: focus on novantrone, Toronto, p. 14, February, 1984

  • Stewart DJ, Green RM, Mikhael NZ, Montpetit V, Thibault M, et al. Human autopsy tissue concentrations of mitoxantrone. Cancer Treatment Reports 70: 1255–1261, 1986

    PubMed  CAS  Google Scholar 

  • Stewart DJ, Perrault DJ, Maroun JA, Lefebvre BM. Combined mitoxantrone plus doxorubicin in the treatment of breast cancer. American Journal of Clinical Oncology — Cancer Clinical Trials 10: 335–340, 1987

    Article  CAS  Google Scholar 

  • Stuart-Harris RC, Bozek T, Pavlidis NA, Smith IE. Mitoxantrone: an active new agent in the treatment of advanced breast cancer. Cancer Chemotherapy and Pharmacology 12: 1–4, 1984

    Article  PubMed  CAS  Google Scholar 

  • Stuart-Harris R, Simes RJ, Coates AS, Raghavan D, Devine R, et al. Patient treatment preference in advanced breast cancer: a randomized cross-over study of doxorubicin and mitozantrone. European Journal of Cancer and Clinical Oncology 23: 557–561, 1987

    Article  CAS  Google Scholar 

  • Stuart-Harris RC, Smith IF. Mitoxantrone: a phase II study in the treatment of patients with advanced breast carcinoma and other solid tumours. Cancer Chemotherapy and Pharmacology 8: 179–182, 1982

    Article  PubMed  CAS  Google Scholar 

  • Su RT. Effect of l,4-dihydroxy-5,8-bis(2-(2-hydroxyethylamino) ethyl amino)-9,10-anthracenedione(dihydroxyanthraquinone) on the replication of Simian virus 40 chromosome. Biochemical and Biophysical Research Communications 103: 249–255, 1981

    Article  PubMed  CAS  Google Scholar 

  • Suga J, Saijo N, Shinkai T, Eguchi K, Sasaki Y, et al. Phase II study of mitoxantrone in patients with non-small cell lung cancer. Japanese Journal of Clinical Oncology 16: 147–151, 1986

    PubMed  CAS  Google Scholar 

  • Taylor WB, Cantwell BMJ, Roberts JT, Harris AL. Allergic reactions to mitoxantrone. Correspondence. Lancet 1: 1439, 1986

    Article  PubMed  CAS  Google Scholar 

  • Taylor SA, Fleming T, Von Hoff DD, McCracken JD, Bukowski RM, et al. Phase II evaluation of mitoxantrone in advanced pancreatic carcinoma: a Southwest Oncology Group study. Investigational New Drugs 8: 77–80, 1990

    PubMed  CAS  Google Scholar 

  • Taylor SA, Von Hoff DD, Baker LH, Balcerzak SP. Phase II clinical trial of mitoxantrone in patients with advanced renal cell carcinoma: a Southwest Oncology Group study. Cancer Treatment Reports 68: 919–920, 1984

    PubMed  CAS  Google Scholar 

  • tenBokkel Huinink WW, Kroes J, Dubbelman R, Franklin H, McVie JG. Intraperitoneal mitoxantrone (M) in refractory ovarian cancer, a dose finding study. Abstract. 5th NCI-EORTC Symposium, Netherlands, p. 9, 1986

    Google Scholar 

  • Tepmongkol P, Suphaphongs N, Thansakul A, Jirapanuwat S, Skulchan V, et al. Mitoxantrone as single agent in the treatment of advanced breast cancer: clinical experience at Siriraj Hospital. Journal of the Medical Association of Thailand 72: 82–88, 1989

    PubMed  CAS  Google Scholar 

  • Tewey KM, Chen GL, Nelson EM, Liu LF. Intercalative anti-tumor drugs interfere with the breakage-reunion reaction of mammalian DNA topoisomerase II. Journal of Biological Chemistry 259: 9182–9187, 1984a

    PubMed  CAS  Google Scholar 

  • Tewey KM, Rowe TC, Yong L, Halligan BD, Liu LF. Adriamycin-induced DNA damage mediated by mammalian DNA topoisomerase II. Science 226: 466–468, 1984b

    Article  PubMed  CAS  Google Scholar 

  • Tham P, Dougherty W, Iatropoulos MJ, Gordon G, James VC, et al. The effect of mitoxantrone treatment in beagle dogs previously treated with minimally cardiotoxic doses of doxorubicin. American Journal of Pathology 128: 121 -130, 1987

    PubMed  CAS  Google Scholar 

  • Thompson PI, Harvey VJ. A phase II study of mitozantrone in advanced breast cancer. Abstract. British Journal of Cancer 58: 268, 1988

    Article  Google Scholar 

  • Thürlimann B, Senn HJ, Jungi WF. Anthracycline-carboplatin combination in metastatic breast cancer. Journal of Cancer Research and Clinical Oncology 116: 13–14, 1990

    Article  PubMed  Google Scholar 

  • Tomirotti M, Perrone S, Farina G, Cobelli S, Scanni A. Mitoxantrone in monochemioterapia neirepatocarcinoma in fase avanzata. Risultati preliminari. Abstract 121. Tumori 75 (Suppl. 4): 42, 1–989 Traganos F, Evenson DP, Staiano-Coico L, Darzynkiewicz Z, Melamed MR. Action of dihydroxyanthraquinone on cell cycle progression and survival of a variety of cultured mammalian cells. Cancer Research 40: 671–681, 1980

    Google Scholar 

  • Tsuruo T, Iida H, Nojiri M, Tsukagoshi S, Sakurai Y. Circumvention of vincristine and adriamycin resistance in vitro and in vivo by calcium influx blockers. Cancer Research 43: 2905–2910, 1983

    PubMed  CAS  Google Scholar 

  • Tsuruo T, Iida H, Tsukagoshi S, Sakurai Y. Increased accumulation of vincristine and adriamycin in drug-resistant P388 tumor cells following incubation with calcium antagonists and calmodulin inhibitors. Cancer Research 42: 4730–4733, 1982

    PubMed  CAS  Google Scholar 

  • Tsuruo T, Kawabata H, Nagumo N, Iida H, Kitatani Y, et al. Potentiation of antitumor agents by calcium channel blockers with special reference to cross-resistance patterns. Cancer Chemotherapy and Pharmacology 15: 16–19, 1985

    Article  PubMed  CAS  Google Scholar 

  • Tumminello FM, Leto G, Gebbia N, Gebbia V, Russo A, et al. Acute myocardial effects of mitoxantrone in the rabbit. Cancer Treatment Reports 71: 529–531, 1987

    PubMed  CAS  Google Scholar 

  • Ungerleider RS, Pratt CB, Vietti TJ, Holcenberg JS, Kamen BA, et al. Phase I trial of mitoxantrone in children. Cancer Treatment Reports 69: 403–407, 1985

    PubMed  CAS  Google Scholar 

  • Unverferth DV, Bashore TM, Magorien RD, Fetters JK, Neid-hart JA. Functional characteristics of human heart after mitoxantrone. Cancer Treatment Symposia 3: 47–53, 1984

    Google Scholar 

  • Unverferth DV, Unverferth BJ, Balcerzak SP, Bashore TA, Neidhart JA. Cardiac evaluation of mitoxantrone. Cancer Treatment Reports 67: 343–350, 1983

    PubMed  CAS  Google Scholar 

  • Uzuka Y, Saito Y, Takahashi H, Komatsu M, Ho T, et al. Multi-agent combination chemotherapy for adult acute lymphoblastic leukemia-individualized chemotherapy. (In Japanese) Japanese Journal of Cancer Chemotherapy 17: 1917–1923, 1990

    CAS  Google Scholar 

  • Van Belle SJP, de Planque MM, Smith IE, van Oosterom AT, Schoemaker TJ, et al. Pharmacokinetics of mitoxantrone in humans following single-agent infusion or intra-arterial injection therapy or combined-agent infusion therapy. Cancer Chemotherapy and Pharmacology 18: 27–32, 1986

    Article  PubMed  Google Scholar 

  • Van Oosterom AT, Fossa SD, Mulder JH, Calciati A, de Pauw M, et al. Mitoxantrone in advanced bladder carcinoma. A phase II study of the EORTC Genito-Urinary Tract Cancer Cooperative Group. European Journal of Cancer and Clinical Oncology 21: 1013–1014, 1985

    Article  Google Scholar 

  • Van Oosterom AT, Fossa SD, Pizzocaro G, Bergerat JP, Bono AV, et al. Mitoxantrone in advanced renal cancer: a phase II study in previously untreated patients from the EORTC Genito-Urinary Tract Cancer Cooperative Group. European Journal of Cancer and Clinical Oncology 20: 1239–1241, 1984

    Article  Google Scholar 

  • Veenhof KHN, George M, Forni M, Tumolo S, ten Bokkel Huinink WW, et al. Phase II study of mitoxantrone in patients with recurrent and/or disseminated endometrial carcinoma. Abstract. Proceedings of the 4th European Conference on Clinical Oncology and Cancer Nursing, Madrid 1987: 209, 1987

  • Veenhof KHN, George M, Forni M, Tumolo S, Rotmensz N, et al. Mitoxantrone in advanced and/or recurrent endometrial carcinoma. Correspondence. European Journal of Cancer 26: 650, 1990

    Article  PubMed  CAS  Google Scholar 

  • Ventura GJ, Keating MJ, Castellanos AM, Glass JP. Reversible bilateral lateral rectus muscle palsy associated with high-dose cytosine arabinoside and mitoxantrone therapy. Cancer 58: 1633–1635, 1986

    Article  PubMed  CAS  Google Scholar 

  • Vile GF, Winterbourn CC. Microsomal lipid peroxidation induced by adriamycin, epirubicin, daunorubicin and mitoxantrone: a comparative study. Cancer Chemotherapy and Pharmacology 24: 105–108, 1989

    Article  PubMed  CAS  Google Scholar 

  • Villalon AH, Tudtud DM, Machica MEG. Phase II evaluation of mitoxantrone in patients with advanced nasopharyngeal carcinoma. Philippines Journal of Internal Medicine 28: 169–176, 1990

    Google Scholar 

  • Villani F, Galimberti M, Crippa F. Evaluation of ventricular function by echocardiography and radionuclide angiography in patients treated with mitoxantrone. Drugs Under Experimental and Clinical Research 15: 501–506, 1989

    PubMed  CAS  Google Scholar 

  • Von Hoff DD, Chen T, Clark GM, Callahan SK, Livingston R, et al. Mitoxantrone for treatment of patients with refractory small cell carcinoma of the lung: a Southwest Oncology Group study. Cancer Treatment Reports 67: 403–404, 1983a

    Google Scholar 

  • Von Hoff DD, Coltman Jr CA, Forseth B. Activity of mitoxantrone in a human tumor cloning system. Cancer Research 41: 1853–1855, 1981

    Google Scholar 

  • Von Hoff DD, Pollard E, Kuhn J, Murray E, Coltman Jr CA. Phase I clinical investigation of l,4-dihydroxy-5,8-bis (( (2-[(2-hydroxyethyl)amino]ethyl)amino))-9,10-anthracenedione dihydrochloride (NSC 301739), a new anthracenedione. Cancer Research 40: 1516–1518, 1980

    Google Scholar 

  • Von Hoff DD, Turner JN, McConnell KI, Coltman Jr CA. The acute toxicities of Novantrone®. Proceedings of the Symposium on the Current Status of Novantrone, March 21–24, pp. 29–34, 1985

  • Vorobiof DA, Iturralde M, Falkson G. Assessment of ventricular function by radionuclide angiography in patients receiving 4′-epidoxorubicin and mitoxantrone. Cancer Chemotherapy and Pharmacology 15: 253–257, 1985

    Article  PubMed  CAS  Google Scholar 

  • Vorobiof DA, Terblanche APS, Falkson CI, Falkson G. Cyclophosphamide, mitoxantrone, vincristine and prednisone in the treatment of non-Hodgkin’s lymphoma. Oncology 45: 378–379, 1988

    Article  PubMed  CAS  Google Scholar 

  • Vredenburgh JJ, Mclntyre OR, Cornwell III GG, Ball ED, et al. Mitoxantrone in relapsed or refractory acute nonlymphocytic leukemia. Medical and Pediatric Oncology 16: 187–189, 1988

    Article  PubMed  CAS  Google Scholar 

  • Waldes H, Center MS. Adriamycin-induced compaction of isolated chromatin. Biochemical Pharmacology 31: 1057–1061, 1982

    Article  PubMed  CAS  Google Scholar 

  • Wallace RE, Citarella RV, Durr FE. The inhibitory effect of 1,4-dihydroxy-5,8-bis[[2-[(2-hydroxyethyl)amino]ethyl]amino]-9,10-anthracenedione dihydrochloride (CL 232315; NSC 301739D) on dividing and non dividing cells in vitro Abstract 49. Proceedings of the American Association of Cancer Research 20: 12, 1979a

    Google Scholar 

  • Wallace RE, Lindh D, Durr FE. Development of resistance and characteristics of a human colon carcinoma subline resistant to mitoxantrone in vitro. Cancer Investigation 5: 417–428, 1987

    Article  PubMed  CAS  Google Scholar 

  • Wallace RE, Murdock KC, Angier RB, Durr FE. Activity of a novel anthracenedione, l,4-dihydroxy-5,8-bis(((2-[(2-hydroxyethyl)amino]ethyl)amino))-9,10-anthracenedione dihydrochloride, against experimental tumors in mice. Cancer Research 39: 1570–1574, 1979b

    PubMed  CAS  Google Scholar 

  • Walters RS, Kantarjian HM, Keating MJ, Plunkett WK, Estey EH, et al. Mitoxantrone and high-dose cytosine arabinoside in refractory acute myelogenous leukemia. Cancer 62: 677–682, 1988

    Article  PubMed  CAS  Google Scholar 

  • Wang BS, Lumanglas AL, Silva J, Ruszala-Mallon VM, Durr FE. Effect of hyperthermia on the sensitivity of human colon carcinoma cells to mitoxantrone. Cancer Treatment Reports 71: 831–836, 1987

    PubMed  CAS  Google Scholar 

  • Wang BS, Lumanglas AL, Silva J, Ruszala-Mallon VM, Durr FE. Inhibition of the induction of alloreactivity with mitoxantrone. International Journal of Immunopharmacology 8: 967–973, 1986

    Article  PubMed  CAS  Google Scholar 

  • Watkin SW, Green JA. CMPP chemotherapy for intermediate and high grade non-Hodgkin’s lymphoma in the elderly. Abstract. British Journal of Cancer 58: 270, 1988

    Google Scholar 

  • Waxman J, Abel P, James N, Farah N, O’Donoghue EPN, et al. New combination chemotherapy programme for bladder cancer. British Journal of Urology 63: 68–71, 1989

    Article  PubMed  CAS  Google Scholar 

  • Weber G. Recent advances in the design of anticancer chemotherapy. Oncology 37 (Suppl. 1): 19–24, 1980

    Article  PubMed  CAS  Google Scholar 

  • Westendorf J, Marquardt H, Groth G, Marquardt H. Genotoxicity of the new potent cancer chemotherapeutic agent mitoxantrone. Abstract 109. Naunym Schmeideberg’s Archives of Pharmacology 329 (Suppl.): R28, 1985

    Google Scholar 

  • Wheeler H, Woods RL, Page J, Levi J. A phase II study of mitoxantrone in advanced squamous cell cancer of the head and neck. Investigational New Drugs 8: 109–111, 1990

    Article  PubMed  CAS  Google Scholar 

  • WHO handbook for reporting results of cancer treatment. Geneva, WHO Offset Publication No. 48, 1979

  • Wilkinson PM, Bevan K, Edmundson J, Lucas SB. Pharmacokinetics of mitoxantrone in patients with metastatic breast cancer (MBC) with liver metastases. Abstract 115. Proceedings of the American Society of Clinical Oncologists 5: 30, 1986

    Google Scholar 

  • Williams SD, Birch R, Gams R, Irwin L. Phase II trial of mitoxantrone in refractory germ cell tumors: a trial of the Southeastern Cancer Study Group. Cancer Treatment Reports 69: 1455–1456, 1985a

    PubMed  CAS  Google Scholar 

  • Wiliams SD, Birch R, Velez-Garcia E, Gams R. Phase II study of mitoxantrone in advanced squamous cell carcinoma of the head and neck. A Southeastern Cancer Study Group trial. Investigational New Drugs 3: 311–313, 1985b

    Article  Google Scholar 

  • Williams M. Preliminary results with novantrone in advanced breast cancer. Proceedings of the 2nd UK Novantrone Symposium, pp. 73–75, 1986

  • Wilson KS, Paterson AHG. First-line mitoxantrone chemotherapy for advanced breast cancer. Cancer Treatment Reports 70: 1021–1022, 1986

    PubMed  CAS  Google Scholar 

  • Wolf CR, MacPherson JS, Smyth JF. Evidence for the metabolism of mitozantrone by microsomal glutathione transferases and 3-methylcholanthrene-inducible glucuronosyl transferases. Biochemical Pharmacology 35: 1577–1581, 1986

    Article  PubMed  CAS  Google Scholar 

  • Yamane T, Inoue T, Furukawa Y, Sasaki A, Kishida T, et al. Treatment of acute leukemia with “MB-triple V” therapy — a comparative study of “MB-triple V” therapy and B-triple V therapy. (In Japanese) Japanese Journal of Cancer Chemotherapy 16: 3729–3733, 1989

    CAS  Google Scholar 

  • Yap H-Y, Blumehschein GR, Schell FC, Buzdar AU, Valdivieso M, et al. Dihydroxyanthracenedione: a promising new drug in the treatment of metastatic breast cancer. Annals of Internal Medicine 95: 694–697, 1981

    PubMed  CAS  Google Scholar 

  • Yoshida T, Okazaki N, Yoshino M, Ohkura H, Miyamoto K, et al. Phase II trial of mitoxantrone in patients with hepatocellular carcinoma. European Journal of Cancer and Clinical Oncology 24: 1897–1898, 1988

    Article  CAS  Google Scholar 

  • Zamboglou N, Schmidt C, Pape H, Fürst G, Schmitt G. Aspekte der kombinierten Radio- und Chemotherapie bei fortgeschrittenen Kopf-Hals-Tumoren. Tumor Diagnostik und Therapie 9: 35–40, 1988

    Google Scholar 

  • Zbinden G, Beilstein AK. Comparison of cardiotoxicity of two anthracenediones and doxorubicin in rats. Toxicology Letters 11:289–297, 1982

    Article  PubMed  Google Scholar 

Download references

Author information

Authors and Affiliations

Authors

Additional information

Various sections of the manuscript reviewed by: J Blanz, Departments of Haematology and Oncology, Medizinische Universitätsklinik, and Institut für Organische Chemie der Universität Tübingen, Tübingen, Federal Republic of Germany; G. Bonadonna, Division of Medical Oncology, Istituto Nazionale Tumori, Milan, Italy; M.A. Chaudary, Hedley Atkins Breast Unit, Imperial Cancer Research Fund Clinical Oncology Unit, Guy’s Hospital, London, England; G. Ehninger, Departments of Haematology and Oncology, Medizinische Universitätsklinik, and Institut für Organische Chemie der Universität Tübingen, Tübingen, Federal Republic of Germany; E. Heidemann, Abteilung Innere Medizin II, Diakonissenkrankenhaus, Stuttgart, Federal Republic of Germany; I.C. Henderson, Division of Medical Oncology, Dana-Farber Cancer Institute, Boston, Massachusetts, USA; P.O.M. Mulder, Department of Internal Medicine, University Hospital, Gröningen, The Netherlands; T. Ohnoshi, Department of Medicine, Okayama University Medical School, Okayama, Japan; C.L. Shapiro, Division of Medical Oncology, Dana-Farber Cancer Institute, Boston, Massachusetts, USA

Rights and permissions

Reprints and permissions

About this article

Cite this article

Faulds, D., Balfour, J.A., Chrisp, P. et al. Mitoxantrone. Drugs 41, 400–449 (1991). https://doi.org/10.2165/00003495-199141030-00007

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.2165/00003495-199141030-00007

Keywords

Navigation